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Abstract 
A structure-based virtual screening of commercial compounds was carried out on the HCV NS3 helicase 
structure, with the aim to identify novel inhibitors of HCV replication. Among a selection of 13 
commercial structures, one compound was found to inhibit the subgenomic HCV replicon in the low 
micromolar range. Different series of new piperazine-based analogues were designed and synthesized, 
and among them, several novel structures exhibited antiviral activity in the HCV replicon assay. Some 
of the new compounds were also found to inhibit HCV NS3 helicase function in vitro, and one directly 
bound NS3 with a dissociation constant of 570 ± 270 nM. 
 
Highlights  Virtual screening studies on the HCV NS3 helicase.  Identification of a substituted piperazine as new anti-HCV scaffold.  Synthesis of different series of novel piperazine-based structures.  New inhibitors of the subgenomic HCV replicon 1b genotype identified.  Novel inhibitors of the HCV NS3 helicase discovered. 
 
Key words 
Structure-based virtual screening; HCV NS3-helicase; piperazine derivatives; anti-HCV activity; NS3 
helicase inhibitors. 
 
1. Introduction 
The hepatitis C virus (HCV) is a major cause of chronic liver disease because it infects approximately 
3% of the global population [1]. HCV infection becomes chronic in 60-85% of patients, who are at high 
risk of developing hepatic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma [2, 3]. An HCV 
vaccine is currently not available, while the standard of care for many years was a combination of 
pegylated interferon (pegIFN) and ribavirin, a therapy that was not specific for HCV, was effective in 
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only 50% of HCV patients, and was associated with many side effects [4]. However, new interferon-free 
combinations of direct acting antivirals (DAAs) have revolutionized HCV prognosis and treatment.  
HCV has a ~9,000 nt long single-stranded, positive-sense RNA genome, which encodes six non-
structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) essential for virus replication [5]. The 
new FDA approved DAAs are highly potent inhibitors of the NS3 protease [6, 7], the NS5B polymerase 
[8], and the NS5A protein [10]. Drugs still in development target other HCV proteins, like NS4B [9].  
All-oral combination therapies with NS5B polymerase, NS3 protease and/or NS5A inhibitors are now 
the standard of HCV care, but they are associated with high costs [11, 12], and resistant mutants have 
been reported for each approved DAA [13-17]. Due to these limitations, new therapeutics that will reduce 
the costs of treatment and avoid the development of resistance are still needed. 
In the search for novel inhibitors of HCV replication, a still underexploited target remains the HCV NS3 
helicase, for which relatively few specific inhibitors have been reported so far, none reaching the clinical 
evaluation stage [18]. The HCV helicase is essential for HCV replication [19, 20], and is most likely 
needed for ATP-dependent unwinding of double-stranded RNA sequences formed during HCV 
replication [21, 22]. An HCV helicase inhibitor was also recently shown to enhance the efficacy of the 
latest generation of HCV protease inhibitors [23]. 
Due to its essential role and relative lack of selective inhibitors under development, the HCV NS3 
helicase was chosen as a target for the in silico identification and synthesis of antivirals, through their 
potential interference with the known RNA binding cleft. 
 
2 Results and discussion 
 
2.1 Molecular modelling 
The HCV NS3 helicase occupies the C-terminal portion of the NS3 protein and is formed by three 
domains, which define an ATP binding pocket in the cleft separating domain 1 from domain 2, and a 
single-stranded nucleic acid binding site at the interface of the three domains (Figure 1) [24].  
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Figure 1: NS3 helicase domains and binding sites within the 3KQN crystal structure [25].  
 
As revealed in several crystal structures available for the enzyme in complex with ssDNA or ssRNA 
oligonucleotides [25, 26], the nucleic acid is bound within the closed conformation of the enzyme in a 
narrow central space defined by the three main domains (Figure 1). Due to the essential role 
demonstrated for Thr269, Arg393, Thr411 and Trp501 [27], computer-based studies were directed to 
identify compounds binding the region defined by these residues. In particular, the sub-site defined by 
Trp501 and Arg393 in the 3KQN crystal structure [25] was used for the virtual screening of the SPECS 
library of commercial compounds [28]. The approximately 450,000 structures available were analysed 
with MOE 2014.10 conformational search tool [29]; 500 low-energy conformations were kept for each 
input molecule. The main interactions between the target residues and the co-crystallised substrate were 
considered to build a pharmacophoric query, and the selection was restricted to five features (Figure 2). 
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Figure 2: Pharmacophoric model built on the 3KQN RNA binding cleft. The model consists of a hydrophobic/aromatic group to 
interact with Trp501 (green), a hydrogen-bond acceptor or anion group to interact with Gly255 and Thr269 (orange), a H-bond 
donor to target Asp296 (purple), a H-bond donor and acceptor to interact with Thr298 and Ser297 (yellow) and a hydrogen-bond 
acceptor to target Arg393 (blue). Exclusion volumes are hidden for clarity. 
 
The 3,500 molecules matching the search criteria were further analysed with a molecular docking 
procedure, using Glide in the standard precision SP mode [30]. The output poses were re-scored with the 
Glide extra precision scoring function XP [31], FlexX [32] and Plants ChemPLP [33] scoring functions. 
The rescoring results were combined with a consensus scoring procedure, in which for each scoring 
function a pose is considered a hit if ranked in the top 25% of the score value range for all the poses of 
the database. As a further analysis, the molecules matching this criterion for all three scoring functions 
were re-docked with Glide SP [30] in the RNA binding pocket of the 3KQH crystal structure, which 
corresponds to the high-affinity open conformation of the enzyme. A final selection of 13 derivatives 
was made after visual inspection of the docking results. These compounds were purchased and tested in 
the HCV replicon assay (Table S1). Among them, 1a (Figure 3) showed an interesting antiviral profile 
against HCV replication, with an EC50 value in the low micromolar range (Table 1). 
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Figure 3: Structure and predicted binding mode of 1a in the 3KQH crystal structure. 
 
The predicted binding mode found for 1a indicates good spatial occupation of the target site, with one 
aromatic ring in close proximity to Trp501, the piperazine linker filling the central space surrounding 
Asn556, and the opportunity of hydrogen-bond formation between one sulfonamido group and Arg393 
and Thr411 backbone (Figure 3). Given its potential to inhibit HCV replication, a series of derivatives 
of 1a was designed and prepared for further investigations. 
 
2.2 Chemistry 
Compound 1a is characterised by a symmetrical structure, with a central piperazine ring and two aliphatic 
linkers connected by a sulfonamide group to two equal aromatic systems. The main modifications 
designed included different aromatic substitutions, linker chain variations and disruption of the molecule 
symmetry, as summarised in Figure 4.  
 
Figure 4: Proposed modifications on the scaffold of 1a. 
 
A first series of new derivatives was designed to explore the effect of the aromatic substituent on the 
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original structure, by varying the substitutions on the phenyl rings while keeping the central piperazine 
nucleus, maintaining the original three-carbon saturated linker or symmetrically shortening it to a two-
carbon chain. Different commercially available aromatic sulfonyl chlorides (2a-s) and sulphonamide 5 
were used to obtain piperazine derivatives 1a-u and 8a-h according to an optimised two-step synthetic 
pathway (Scheme 1). A further modification was designed to rigidify the three-carbon linker and study 
the importance of the positive charge/H-bond acceptors of the piperazine amine groups, inserting an 
amide group in correspondence of piperazine nitrogen atoms, using the scaffold of -alanine (8) as new 
linker for a third series of symmetrical compounds 11a, d, f-h (Scheme 1). 
 
 
Scheme 1: Reagents and conditions: a) i. Et3N, an. DCM, 0 °C, 10 min; ii. NaH, DMF, rt, 1h, followed by 1,3-dibromopropane, 0 
°C, 10 min; iii. piperazine, NaHCO3, EtOH, reflux, 24h; iv. LiOH, THF, H2O, 80 °C, on. b) i. NaOH, H2O, 35 °C, 2h; ii. TBTU, 
HOBt, DiPEA, an. THF, rt, 4h. 
 
The strategy to obtain amine compounds 1a-s and 8a-h began with the preparation of sulfonamides 6a-
s and 7a-h, all obtained with a nucleophilic displacement of amino alkylbromides 3-4 and the different 
sulfonylchlorides. In order to avoid a self-reaction between two molecules of the nucleophile, the amine 
group of the alkyl bromides was slowly released by the dropwise addition of triethylamine at 0 C. 6u 
was obtained by treating sulfonamide 5 with sodium hydride, followed by the addition of 1,3-
dibromopropane. Final symmetrical products 1a-s, 1u and 8a-h were obtained through the displacement 
of the intermediate bromide leaving groups by piperazine, using NaHCO3/ethanol as base/solvent system 
and refluxing the reaction mixture for 24 h. Compound 1t, with a carboxylic function on the aromatic 
rings, was obtained after basic hydrolysis of ester 1s. Symmetrical amide products 11a, d, f-h were 
obtained reacting the different sulfonyl chlorides with -alanine 9, with the formation of carboxylic acid 
intermediates 10a-d, f-h, l, n, which were subsequently used for a coupling reaction with piperazine, 
using TBTU as coupling agent. With the purpose to further explore the role of the aliphatic linker, its 
elongation was also envisaged: compound 17 with a four-carbon linker was obtained after optimisation 
of a four-step synthetic pathway (Scheme 2). 
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Scheme 2: Reagents and conditions: (i) Et3N, an. DCM, rt, 7h; (ii) Mesyl chloride, Et3N, an. DCM, rt, 2h; (iii) Piperazine, NaHCO3, 
EtOH, reflux, 24h; (iv) TFA, H2O, rt, 30min, followed by 2a, Et3N, an. DCM, 0 °C to rt, 1h. 
 
The free amine in 4-aminobutanol 12 was first protected with BOC to give 14, and then the hydroxy 
function was converted to mesylate ester in 15. Once displaced the mesylate groups with piperazine (16), 
the two terminal amine groups were deprotected by hydrolysis of the carbamate ester with trifluoroacetic 
acid, thus obtaining an intermediate salt, which was precipitated from the reaction mixture and directly 
treated with an excess of 4-chloro-benzenesulfonyl chloride (2a) in basic conditions to give 17. 
The role of the sulfonamide groups was also explored by replacement with amide functions in 20 
(Scheme 3a), obtained by reacting acyl chloride 18 with alkyl bromide 3, and then treating intermediate 
19 with piperazine at r.t. in THF. Moreover, an attempt to investigate the importance of the piperazine 
central nucleus was made by replacing it with a para-phenylendiamine group in 21, which maintains the 
overall length of the original scaffold (Scheme 3b). 
 
Scheme 3: Reagents and conditions: a) i. Et3N, an. DCM, 0 °C, 10 min; ii. Piperazine, Et3N, an. THF, rt, 48 h; b) i. p-
Phenylendiamine, Et3N, an. THF, rt, 72 h. 
 
Finally, the role of molecular symmetry for antiviral activity was also taken into consideration, and three 
small series of unsymmetrical compounds were designed and synthesised. All the compounds prepared 
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followed a rational approach guided by the biological results obtained for the previous series of 
structures. In particular, the presence of two aromatic sulfonamide groups was to be maintained, along 
with a para hydrophobic substituent in at least one phenyl ring, the central piperazine nucleus and at 
least one three-carbon linker (Scheme 4). As a further confirmation of the importance of the central 
disubstituted piperazine, derivative 39, in which only half of the original molecule is present, was 
prepared by reacting intermediate 6a with piperidine 38, as shown in Scheme 4. 
 
Scheme 4: Reagents and conditions: a) i. Piperazine, NaHCO3, EtOH, reflux, 24h; ii. 6b-c, l-n, NaHCO3, EtOH, reflux, 24h. b) i. 
NaHCO3, EtOH, reflux, 24h. c) i. TBTU, HOBt, DiPEA, an. THF, rt, 4h. d) i. NaHCO3, EtOH, reflux, 24h. 
 
A first series of unsymmetrical compounds 23-35 was designed to maintain the original scaffold while 
introducing different para hydrophobic substituents in the two aromatic rings, combining together the 
most successful substitutions previously found (4-chloro, 4-methyl, 4-tert-butyl and 4-trifluoromethyl), 
along with the unsubstituted phenyl moiety and the biphenyl one. To achieve this result, the two amine 
groups of piperazine had to be functionalised with two different alkyl bromides: first the pure 
monosubstitution products were isolated, and then these intermediates were reacted with the second alkyl 
bromide. A second small series of unsymmetrical derivatives 36a-b, l was designed to maintain the same 
para hydrophobic substituent in the two aromatic rings, while reducing the length of one linker from 
three to two methylene groups. Final products 36a-b, l were obtained by reacting mono-substituted 
intermediates 22 with ethyl bromides 7a-b, l. A third and final series of unsymmetrical structures 37a-c, 
l, n was planned to functionalise one piperazine amine group to amide, thus partially rigidifying the 
scaffold, while keeping the overall length of the molecule and the same hydrophobic substituent in the 
para position of the two aromatic rings. Mono-substituted intermediates 22a-c, l, n were reacted with 
carboxylic acids 10a-c, l, n, following a TBTU-assisted coupling reaction. Finally, half-molecule 
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derivative 39 was obtained by refluxing intermediate 6a with piperidine 38 in EtOH for 24 hours, using 
NaHCO3 as base. 
 
2.3 Biological activity 
 
2.3.1 HCV replicon and cytostatic assay 
All the newly synthesised compounds were evaluated for their potential antiviral activity in the Huh5-2 
replicon system (Table 1) [34]. The HCV protease inhibitor telaprevir (VX-950) was included as positive 
control. 
  
Table 1: Antiviral effect of the test compounds on hepatitis C virus replication in the Huh5-2 replicon system and inhibition of 
NS3 helicase unwinding activity. 
Compound EC50(M)a,d EC90(M)b,d CC50(M)c,d SIe Unwinding 
IC50 (µM)f 
1a 13.8±0.531 - >182 >13.2 >1000 
1b 58.3 - >104 >1.8 n.d. 
1c 19.2 - >197 >10.3 n.d. 
1d >92.5 >92.5 >92.5 - n.d. 
1e 18.1±1.57 61.1 77.4 4.4 n.d. 
1f 82 >166 >166 >2 n.d. 
1g >83.2 >83.2 >83.2 - n.d. 
1h 4.9 - 49.9 10 460±430 
1i 76.9±18.2 173 >182 >2.4 n.d. 
1l 8.7±5.03 42.9±34.1 97.2±17.1 11.2 310±190 
1m 6.5 - >162 >25 >1000 
1n 1.2 - 4.9 3.9 630±270 
1o >172 >172 >172 - >1000 
1p 42.5±15.3 >172 >172 >4 >1000 
1q 62±14.4 156 >203 >3.3 n.d. 
1r >207 >207 >207 - n.d. 
1s 56.2±3.2 - >160 >2.8 >1000 
1t >176 - >176 - >1000 
1u 39.6±9.03 >182 >182 >4.6 n.d. 
8a >95.9 - >95.9 - 250±110 
8b >110 - >110 - n.d. 
8c >104 >104 >104 - n.d. 
8d >97.5 >97.5 >97.5 - n.d. 
8e 17.4±5.56 - >184 >10.6 n.d. 
8f 85.8 >87.3 >87.3 >1 n.d. 
8g >87.3 - >87.3 - n.d. 
8h 10.6 - >90.5 >8.5 690±350 
11a - - >86.6 - >1000 
11d - - >87.9 - n.d. 
11f >159 >159 >159 - n.d. 
11g >79.5 - >79.5 - n.d. 
11h 12±4.24 - 40.8 3.4 n.d. 
17 66.7±12.5 164 >173 >2.5 790±270 
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20 >209 >209 >209 - n.d. 
21 12.1 - 22 1.8 n.d. 
23 19.9±6.07 >64 81.5±30.4 4.1 n.d. 
24 9.93±3.34 36 48.8±4.8 4.9 n.d. 
25 2.21±0.747 4.96 8.77±1.47 4 310±66 
26 10.1±0.799 33.5±5.72 63.7±12.8 6.3 n.d. 
27 2.12±0.722 - 4.43±0.845 2.1 n.d. 
28 3.74±0.878 - 20.5±6.64 5.5 n.d. 
29 3.5±0.664 9.44 14.6±1.44 4.2 n.d. 
30 6.62±2.34 13.8±6.02 28.7±9.07 4.3 >1000 
31 1.3±0.777 3.05±1.12 4.78±1.53 3.7 90±30 
32 26.3±6.25 - 138 5.3 n.d. 
33 1.98±0.307 - 6.55±1.3 3.3 n.d. 
34 4±2.49 - 14±3.4 3.5 >1000 
35 12.1±1.36 - 70.8±13 5.8 n.d. 
36a 6.59±2.03 - 32.3±7.34 4.9 n.d. 
36b 69.2±21 212 >214 >3.1 n.d. 
36l 1.7±0.17 - 5.21±1.51 3.1 170±30 
37a 9.32±5.44 25.9±6.32 69.1 7.4 >1000 
37b >202 >202 >202 - n.d. 
37c 64.3±2.24 173 >191 >3 n.d. 
37l 3.84±1.34 - 20.8±10.7 5.4 >1000 
37n 3.03±0.226 - 66.9±50.2 22.1 >1000 
39 61.9 - 145 2.3 n.d. 
(VX-950) 0.8±0.2 - 47 58.8 n.d. 
Primuline - - - - 10±2 
Aurintricarboxylic 
Acid 
- - - - 0.3± 0.1 
a EC50 = 50% effective concentration (concentration at which 50% inhibition of virus replication is observed). 
b EC90 = 90% effective concentration (concentration at which 50% inhibition of virus replication is observed). 
c CC50 = 50% cytostatic/cytotoxic concentration (concentration at which 50% adverse effect is observed on the host cell). 
d The EC50, EC90 and CC50 values are the mean of at least 2 independent experiments, with standard deviations of ±10% of the 
value quoted unless otherwise stated (mean value ± standard deviations). 
e
 SI = the ratio of CC50 to EC50. 
f Concentration needed to reduce rates of helicase-catalysed DNA unwinding by 50%  
n.d. Not determined 
 
Considering the results obtained for 1a-t, most of the antiviral potential is associated with a hydrophobic 
substituent in the para position of the two aromatic rings, as can be observed for 1a, 1c, 1l and 1m. 
Moreover, moving the original 4-chloro group to position 3 (1i) or 2 (1u) is associated with activity 
reduction. The lowest EC50 value is reached when a second phenyl group is placed in the position 4 of 
the two aromatics (1n), although this modification also shows an increased cytotoxic effect. Compounds 
1e and 1h, with a para-nitrophenyl and 2-naphthyl aromatic moieties respectively, are associated with an 
increased toxic effect in comparison with the other analogues in this series, while the removal of the 
para-substituent or its replacement with methoxy groups leads to loss of activity (1b, d, f, g). 
Replacement of the original phenyl rings with heteroaromatic moieties in 1p-r leads as well to loss of 
activity, and the same effect can be observed for the substitution of the 2-naphthyl group (1h) with a 1-
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naphthyl in 1o: even though cytotoxicity is reduced, any activity against the viral replication is lost. 
Trying to mimic the effect of the 4-nitro group of 1e, a 4-carboxylate function was introduced as aromatic 
substituent in 1t: with this last modification, both cytotoxicity and antiviral activity are abolished. A mild 
inhibition of the viral replication is observed for ethyl ester 1s, but its antiviral potential is reduced in 
comparison with 1a. Symmetrical shortening of the aliphatic linker in 8a-h is associated with loss of 
activity, possibly indicating an important role of the linker for the viral replication inhibition. An 
exception to this trend is represented by 8h and 8e, for which the presence of a 4-nitrophenyl and a 2-
naphthyl rings, respectively, results in activity retention in comparison with their three-carbon 
counterparts, while the shortening of the linker appears to reduce the toxic effect found for 1h and 1e. 
Antiviral results for symmetrical amides 11a, d, f-h indicate that either the presence of the positive charge 
on the piperazine amine groups or the flexibility of the two linkers are important for the viral replication 
inhibition, since this modification is correlated with loss of activity for all seven derivatives prepared. A 
longer aliphatic linker of four methylene groups (17) is also associated with loss of activity, confirming 
that the length of the molecule plays an important role in HCV replication inhibition. Another feature 
that appears important is the presence of the two sulfonamide groups: their replacement with amide 
groups in the symmetrical scaffold of 20 is associated with a dramatic loss of activity. Biological results 
found for 21, where the 4-phenylendiamine central ring both rigidifies the structure and removes the 
positive charge of the linker compared to 1a, suggest an increased cytotoxicity, even if a low micromolar 
EC50 value is retained. The loss of antiviral activity found for 39 indicates the importance of the overall 
length of the molecule, and taken together with the results found for 21 this evidence suggests that the 
presence of a di-substituted piperazine nucleus is essential for the antiviral activity of the novel scaffold. 
Antiviral data found for compounds 23-35 suggest that symmetry is not essential for antiviral activity, 
since the insertion of different para-hydrophobic substituents in the two aromatic rings is tolerated: EC50 
values for most of these compounds are in the range of 1-10 M, suggesting activity retention as a general 
trend. Nevertheless, in some cases the small modification carried out seems to strongly and unexpectedly 
affect cytotoxicity, as revealed for 25 and 28-30. In the case of biphenyl products 27, 31, 33 and 34 this 
cytotoxic effect seems to be at least partially in line with the results obtained for 1n. In the case of 
unsymmetrical compounds 36a-b, l, in which one aliphatic linker is shortened to two methylene groups, 
the small change in the molecular structure is associated with a retained antiviral effect, further 
confirming that symmetry is not required for antiviral activity. Nevertheless, with the exception of 36b, 
also in this second series of unsymmetrical derivatives the small modification is correlated with an 
increased cytotoxic effect. Finally, biological results for unsymmetrical compounds 37a-c, l and n, in 
which one piperazine nitrogen is functionalised to amide, suggest activity retention, with 37a, 37l and 
37n showing EC50 values in the low micromolar range, even though the toxic effect seems to be 
enhanced, particularly for 37l. Data found for 37b, which, as expected, does not show any antiviral 
activity, confirm the essential role played by a para-hydrophobic aromatic group for the viral replication 
inhibition. 
 
2.3.2 HCV NS3 helicase enzymatic assays 
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About half of the newly synthesised compounds were tested for their ability to inhibit HCV NS3 helicase-
catalysed nucleic acid unwinding. Somewhat surprisingly, most compounds tested did not effect 
observed rates of DNA strand separation, even when supplied at concentrations as high as 1 mM (Table 
1). Primuline [18] and aurintricarboxylic acid [35] were included as positive controls. 
The most active compound, 31 (IC50=90±30 µM), was selected for additional analysis along with a 
compound with intermediate activity, 1l (IC50=310±190), and two compounds that did not inhibit 
helicase-catalysed DNA unwinding, 1a and 11a (Figure 5A).  Each compound was tested for its ability 
to either dislodge HCV helicase from a bound oligonucleotide (Figure 5B) or prevent HCV helicase 
from hydrolysing ATP (Figure 5C).  Only 31 was able to fully displace NS3h from an oligonucleotide 
at concentrations below 1 mM (Figure 5B).  Both 31 and 1l inhibited ATP hydrolysis, but again 31 was 
a far more potent inhibitor in this assay (Figure 5C).   
Interestingly, about 10 times less 31 was needed to inhibit NS3h-catalysed ATP hydrolysis than was 
needed to inhibit nucleic acid binding to the same extent. Since small molecules can inhibit helicase-
catalysed ATP hydrolysis either by preventing ATP from binding or by preventing nucleic acids from 
stimulating ATP hydrolysis, we next tested the ability of 31 to inhibit ATP hydrolysis in the absence and 
presence of various concentrations of poly(U) RNA. In the absence of RNA, 31 did not inhibit NS3h-
catalysed ATP hydrolysis even at concentrations as high as 1 mM (data not shown).  However, 31 
inhibited ATP hydrolysis in the presence of RNA in a manner in which 31 appeared to compete with 
RNA for a binding site on the enzyme (Figure 5D).  Data best fit a kinetic model that assumes that 31 
affects the apparent dissociation constant for RNA (KRNA), but does not influence the Vmax.  However, 
unlike what is seen with classic competitive inhibitors, the observed KRNA values were not linearly 
dependent on the concentration of the inhibitor (i.e. 31). Instead, a plot of KRNA vs. 31 concentration 
reveals a sigmoidal relationship, indicative of a cooperative effect (Figure 5E).   
To rule out the possibility that 31 might be acting by binding helicase substrates instead of NS3, we also 
performed direct binding assays by monitoring the effect of 31 on intrinsic protein fluorescence. Both 
NS3h and 31 fluoresce at 340 nm when excited at 280 nm.  When each is alone, NS3h fluoresces about 
70 times more brightly than the same amount of 31 at these wavelengths. However, when a solution of 
NS3h is titrated with 31, a new species forms that fluoresces twice as brightly as free NS3h, and 140 
times brighter than free 31.  Titration data fit a model in which a 1:1 complex forms with a dissociation 
constant of 0.57 µM.  Importantly, this high affinity seems to best reflect the ability of 31 to inhibit 
replication of HCV replicons where the average observed EC50 value was 1.3 µM. 
 
 13 
Figure 5: Inhibition of HCV NS3 helicase activity for the newly synthesised piperazine derivatives. (A) Compounds selected for 
analysis. (B) The ability of each compound to displace NS3h from a DNA oligonucleotide.  Numbers in parenthesis are IC50 values 
with errors representing 95% confidence intervals seen in non-linear regression analysis of 2 independent titrations. (C) Ability of 
each compound to inhibit NS3 helicase-catalysed ATP hydrolysis. Numbers in parenthesis are as in (B).  (C) Rates of ATP 
hydrolysis (nM ATP cleaved/s/nM NS3h) observed in the presence of various concentrations of poly(U) RNA and 31.  Data are 
globally fit to Eq. 1 (Methods) assuming 31 does not affect Vmax.  (E) Amount of RNA needed to stimulate ATP hydrolysis to 50% 
maximum (KRNA) observed at various concentrations of 31. (F)  Fluorescence observed with various concentrations of 31 in the 
absence of NS3h (circles) or in the presence of 100 nM NS3h (squares).  Data are globally fit to Eq. 2 (Methods) with the noted 
dissociation constant and an Fe of 308, Fs of 4.5. and Fc of 641.    
 
These results suggest that enzymatic in vitro reactions might not be the best assays to detect antivirals 
that target a helicase.  The above observation that a compound that clearly binds directly to NS3h fails 
to inhibit the enzyme at concentrations where it should be fully bound suggests that assay conditions 
might prevent the enzyme-inhibitor interaction.  For example, the helicase might form oligomers or 
higher ordered structures when bound to nucleic acids or ATP such that ligand binding is blocked.  
Alternatively, the rapid conformational changes that occur while the helicase acts as a molecular motor 
in these assays might dislodge a bound inhibitor. Based on our results with 31, it is likely that other 
compounds also bind NS3h with high affinity (examples: 1h, 1l-o, 1s-t, 8a, 8h, 17, 30-31, 34, 36l, 37a, 
37l, and 37n). However, testing for at direct interaction between these other compounds and NS3h has 
been challenging because they do not possess the same optical properties as 31.  We are therefore still 
exploring other possible assays to determine the affinity of other compounds generated in this project for 
the HCV helicase, many of which are associated with less cytotoxicity in the replicon assay than 31 
(Table 1).   
Based on the results obtained so far, some inhibition of the enzyme unwinding activity can be observed 
with a naphthyl aromatic ring in the symmetrical structure (1h, 1o, 8h), both with a three or two-carbon 
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linker, with a 4-carboxylic or 4-ethoxylate groups (1s-t), with a 4-chlorophenyl system and a two-carbon 
or four-carbon linker (8a and 17), and with the original three-carbon symmetrical scaffold and a 4-tert-
butylphenyl, 4-CF3-phenyl or a 4-biphenyl ring (1l-n). The trend for the enzymatic activity does not seem 
to parallel the HCV replicon assay, since in this set of data the length of the linker does not play an 
essential role, even if the presence of a bulky hydrophobic substituent in the para position of the aromatic 
ring seems relevant for activity. Some ability to inhibit helicase-catalysed unwinding can also be 
observed in all three series of unsymmetrical structures, in particular with a 4-tert-butyl group in at least 
one aromatic (30-31, 36l, 37l), with at least one biphenyl moiety (31, 34, 37n), or with two equal 4-
chlorophenyl substituents in the unsymmetrical amide scaffold (37a).  
This data would suggest that the antiviral effect of 31, should be at least in part due to its interference 
with the NS3 helicase function, and that several commonly used helicase assays grossly underestimate 
the potency of this, and likely related, compounds. The antiviral effect of the newly prepared structures 
might alternatively result from the interference with an additional target, viral or cellular. Additional 
studies aiming to improve the antiviral activity and understand the mechanism of action of these 
compounds are ongoing and will be reported in due course. 
 
3 Conclusions 
The application of computer-aided techniques to the study of the HCV NS3 helicase led to the 
identification of one commercial piperazine-based analogue with an antiviral effect against HCV 
replication in the low micromolar range. Starting from its structure, different modifications were 
designed and carried out to explore the biological activity associated with the new scaffold. Several 
analogues of 1a inhibited the HCV subgenomic replicon replication. Different structural modifications 
were explored to understand the role of aromatic substituents, sulfonamide groups, linker chains, 
piperazine central nucleus and symmetry of the original molecule. Two equal phenyl rings with a 
hydrophobic substituent in the para position are essential for antiviral activity, along with the presence 
of the two sulfonamide groups and the central piperazine nucleus. The length and nature of the two linker 
chains is also important for activity retention: the presence of at least one three-carbon aliphatic linker is 
essential, while shortening or elongating the two linkers at the same time is associated with loss of 
activity. The same effect can be observed with the symmetrical functionalization of piperazine amine 
groups to amide, by inserting a carbonyl group in the terminal methylene of the two linkers. Replacement 
of the piperazine central ring with para-phenylendiamine is associated with loss of activity, and activity 
is lost as well when piperazine central nucleus is replaced with piperidine, maintaining only half of the 
original scaffold. The overall symmetry of the structure can tolerate small perturbations such as two 
different para hydrophobic aromatic substituents, or different linker chains. Unsymmetrical derivatives 
are in general associated with increased cytotoxicity in comparison with their symmetrical counterparts. 
In vitro evaluations of some of the newly synthesised compounds show that different inhibit the NS3 
helicase activity. In particular, compound 31 bound free helicase with a sub-micromolar dissociation 
constant, and it influenced the protein’s ability to bind nucleic acid substrates needed to stimulate ATP 
hydrolysis.  Even if the antiviral effect of the new structures could be at least partially correlated with 
inhibition of the NS3 helicase, other viral or cellular targets could still be involved, and the toxicity of 
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31 suggests it might also act against related cellular motor proteins. Further exploration of both antiviral 
activity and biological targets of these compounds is the current focus of ongoing investigations. 
 
4 Experimental 
 
4.1 Materials and methods 
All solvents used for chromatography were HPLC grade from Fisher Scientific (UK). 1H and 13C NMR 
spectra were recorded with a Bruker Avance DPX500 spectrometer operating at 500 and 125 MHz, with 
Me4Si as internal standard. Mass spectra were determined with a Bruker microTOF spectrometer using 
electrospray ionization (ESI source). For mass spectra, solutions were made in HPLC grade methanol. 
Flash column chromatography was performed with silica gel 60 (230–400mesh) (Merck) and TLC was 
carried out on precoated silica plates (kiesel gel 60 F254, BDH). Compounds were visualised by 
illumination under UV light (254 nm). Melting points were determined on an electrothermal instrument 
and are uncorrected. All solvents were dried prior to use and stored over 4 Å molecular sieves, under 
nitrogen. All compounds were more than 95% pure. 
 
Intermediates 6-7, 10, 13, 14, 19, 22 were prepared according to literature procedures, described in detail 
along with compound characterisation in the Supporting Information. Preparation and characterisation 
details on the new target compounds 1a-s,u, 8a-h, 11a, d, f-h, 17, 20, 21, 23-35, 37a-c, l, n are given 
below. 1H-NMR spectra of all final compounds are reported in the Supporting Information. 
 
4.1.1 General method for the preparation of N,N’-(piperazine-1,4-diyl)bis 
(alkyl)diarylsulfonamides 1, 8 
Piperazine (0.05 g, 0.6 mmol) and NaHCO3 (0.11 g, 1.3 mmol) were suspended in absolute ethanol (9 
mL). The different alkyl bromide 6 or 7 (1.3 mmol) was then added portionwise to the suspension and 
the reaction mixture was stirred under reflux for 24 h. The solvent was evaporated under reduced pressure 
and the crude residue was purified by flash column chromatography. 
 
4.1.1.1 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-chlorobenzene-sulfonamide) (1a) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 64% yield as a pale yellow solid. M.p. 168-170°C. TLC (9:1 DCM-MeOH, 
Rf: 0.61). 1H-NMR (DMSO-d6), : 1.48-1,52 (m, 4H), 2.18-2.26 (m, 12H), 2.73-2.78 (m, 4H), 7.69 (d, 
J= 8.6 Hz, 4H), 7.71 (bs, 2H), 7.81 (d, J= 8.6 Hz, 4H). 13C-NMR (DMSO-d6), : 26.0, 40.8, 52.5, 54.7, 
128.4, 129.3, 137.1, 139.3. Anal. Calcd for C22H30Cl2N4O4S2: C, 48.08; H, 5.50; N, 10.20. Found: C, 
47.95; H, 5.11; N, 10.07. MS [ESI, m/z]: 549.0, 551.0 [M+H]. 
 
4.1.1.2 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dibenzene-sulfonamide (1b) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 64% yield as a white solid. TLC (9:1 DCM-MeOH, Rf: 0.46). M.p. 136-
138°C. 1H-NMR (CDCl3), : 1.60 (m, 4H), 2.38 (m, 12H), 3.04 (t, J= 5.8 Hz, 4H), 7.10 (bs, 2H), 7.50 
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(m, 4H), 7.56 (m, 2H), 7.83 (m, 4H). 13C-NMR (CDCl3), : 24.0, 44.0, 53.0, 57.9, 126.8, 129.0, 132.6, 
140.1. Anal. Calcd for C22H32N4O4S2: C, 54.98; H, 6.71; N, 11.66. Found: C, 54.85; H, 6.99; N, 11.48. 
MS [ESI, m/z]: 481.1 [M+H]. 
 
4.1.1.3 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-methylbenzene-sulfonamide) (1c) 
[36] 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 95:5 v/v. Obtained in 68% yield as a white solid.  M.p. 176-178°C (lit. 181-183°C) [33]. TLC 
(9:1 DCM-MeOH, Rf: 0.67). 1H-NMR (CDCl3), : 1.65 (m, 4H), 2.46 (bs, 18H), 3.07 (t, J= 5.6 Hz, 4H), 
7.12 (bs, 2H), 7.32 (d, J= 8.2 Hz, 4H), 7.74 (d, J= 8.2 Hz, 4H). 13C-NMR (DMSO-d6), : 20.9, 26.0, 
40.9, 52.6, 54.8, 126.5, 129.5, 137.8, 142.4. Anal. Calcd for C24H36N4O4S2: C, 56.67; H, 7.13; N, 11.01. 
Found: C, 56.89; H, 6.92; N, 11.14. MS [ESI, m/z]: 509.1 [M+H]. 
 
4.1.1.4 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-methoxybenzene-sulfonamide) (1d) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 91:9 v/v. Obtained in 60% yield as a white solid. M.p. 172-174°C. TLC (9:1 DCM-MeOH, Rf: 
0.72). 1H-NMR (DMSO-d6), : 1.47 (m, 4H), 2.18 (bs, 12H), 2.72 (m, 4H), 3.83 (s, 6H), 7.11 (d, J= 8.3 
Hz, 4H), 7.41 (t, J= 5.6 Hz, 2H), 7.70 (d, J= 8.3 Hz, 4H). 13C-NMR (DMSO-d6), : 25.6, 39.7, 51.9, 54.3, 
56.0, 114.4, 126.5, 131.8, 165.2. Anal. Calcd for C24H36N4O6S2: C, 53.31; H, 6.71; N, 10.36. Found: C, 
53.44; H, 6.92; N, 10.40. MS [ESI, m/z]: 541.1 [M+H]. 
 
4.1.1.5 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-nitrobenzene-sulfonamide) (1e) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 91:9 v/v. Obtained in 43% yield as a pale yellow solid. M.p. 226-228°C. TLC (9:1 DCM-MeOH, 
Rf: 0.59). 1H-NMR (DMSO-d6), : 1.49 (m, 4H), 2.18 (m, 12H), 2.82 (t, J= 6.8 Hz, 4H), 7.98 (bs, 2H), 
8.03 (d, J= 8.7 Hz, 4H), 8.42 (d, J= 8.7 Hz, 4H). 13C-NMR (DMSO-d6), : 26.1, 40.8, 52.5, 54.6, 124.5, 
128.0, 146.1, 149.5. Anal. Calcd for C22H30N6O8S2: C, 46.31; H, 5.30; N, 14.73. Found: C, 45.99; H, 
5.63; N, 14.66. MS [ESI, m/z]: 571.1 [M+H]. 
 
4.1.1.6 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(3,4-dimethoxybenzene-sulfonamide) 
(1f) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 95:5 v/v. Obtained in 65% yield as a yellow solid. M.p. 152-154 °C. TLC (9:1 DCM-MeOH, Rf: 
0.70). 1H-NMR (CDCl3), : 1.66 (m, 4H), 2.47 (m, 12H), 3.06 (t, J= 5.7 Hz, 4H), 3.93 (s, 6H), 3.96 (s, 
6H), 6.53 (bs, 2H), 6.95 (d, J= 8.4 Hz, 2H), 7.33 (d, J= 2.1, 2H), 7.46 (dd, J1= 8.4 Hz, J2= 2.1 Hz, 2H). 
13C-NMR (CDCl3), : 24.1, 44.0, 53.0, 56.1, 56.2, 57.7, 109.7, 110.5, 120.7, 131.9,  149.0, 152.3. Anal. 
Calcd for C26H40N4O8S2: C, 51.98; H, 6.71; N, 9.33. Found: C, 51.96; H, 6.94; N, 9.30. MS [ESI, m/z]: 
601.1 [M+H]. 
 
4.1.1.7 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(2,5-dimethoxybenzene-sulfonamide) 
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(1g) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 95:5 v/v. Obtained in 71% yield as a white solid. M.p. 170-172 °C. TLC (9:1 DCM-MeOH, Rf: 
0.73). 1H-NMR (CDCl3), : 1.71 (m, 4H), 2.55 (bs, 12H), 3.00 (t, J= 6.2 Hz, 4H), 3.83 (s, 6H), 3.95 (s, 
6H), 6.22 (bs, 2H), 7.00 (d, J= 8.9 Hz, 2H), 7.08 (dd, J1= 8.9 Hz, J2= 3.1 Hz, 2H), 7.47 (d, J= 3.1, 2H). 
13C-NMR (CDCl3), : 25.3, 44.4, 52.5, 55.4, 56.0, 57.2, 114.1, 114.8, 120.2, 132.0, 150.4, 153.3. Anal. 
Calcd for C26H40N4O8S2: C, 51.98; H, 6.71; N, 9.33. Found: C, 51.80; H, 7.02; N, 9.29. MS [ESI, m/z]: 
601.1 [M+H]. 
 
4.1.1.8 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dinaphthalene-2-sulfonamide (1h) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v.Obtained in 79% yield as a white solid. M.p. 186-188 °C. TLC (9:1 DCM-MeOH, Rf: 
0.62). 1H-NMR (CDCl3), : 1.66 (m, 4H), 2.46 (bs, 12H), 3.13 (t, J= 5.5 Hz, 4H), 7.32 (bs, 2H), 7.66 (m, 
4H), 7.83 (dd, J1= 8.7 Hz, J2= 1.8 Hz, 2H), 7.95 (d, J= 7.9, 2H), 7.99 (m, 4H), 8.44 (s, 2H). 13C-NMR 
(DMSO-d6), : 25.9, 40.8, 52.4, 54.7, 122.2, 127.3, 127.5, 127.7, 128.6, 129.1, 129.3, 131.7, 134.0, 
137.4. Anal. Calcd for C30H36N4O4S2: C, 62.04; H, 6.25; N, 9.65. Found: C, 61.89; H, 5.97; N, 9.48. MS 
[ESI, m/z]: 581.1 [M+H]. 
 
4.1.1.9 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(3-chlorobenzene-sulfonamide) (1i) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 79% yield as a white solid. M.p. 156-158 °C. TLC (9:1 DCM-MeOH, Rf: 
0.66). 1H-NMR (DMSO-d6), : 1.48 (m, 4H), 2.20 (m, 12H), 2.79 (m, 4H), 7.64 (t, J= 7.8 Hz, 2H), 7.74 
(m, 6H), 7.78 (t, J= 1.8 Hz, 2H). 13C-NMR (DMSO-d6), : 26.0, 40.8, 52.5, 54.7, 125.1, 126.0, 131.3, 
132.2, 133.8, 142.4. Anal. Calcd for C22H30Cl2N4O4S2: C, 48.08; H, 5.50; N, 10.20. Found: C, 47.90; H, 
5.76; N, 10.08. MS [ESI, m/z]: 549.0, 551.0 [M+H]. 
 
4.1.1.10 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-tertbutylbenzene-sulfonamide) (1l) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 82% yield as a white solid. M.p. 188-190 °C. TLC (9:1 DCM-MeOH, Rf: 
0.59). 1H-NMR (DMSO-d6), : 1.31 (s, 18H), 1.46 (m, 4H), 2.16 (m, 12H), 2.75 (m, 4H), 7.49 (t, J= 5.8 
Hz, 2H), 7.60 (d, J= 8.4 Hz, 4H), 7.70 (d, J= 8.4 Hz, 4H). 13C-NMR (DMSO-d6), : 26.0, 30.7, 34.7, 
40.8, 52.5, 54.8, 125.9, 126.3, 137.6, 155.1. Anal. Calcd for C30H48N4O4S2: C, 60.78; H, 8.16; N, 9.45. 
Found: C, 60.96; H, 8.00; N, 9.51. MS [ESI, m/z]: 593.3 [M+H]. 
 
4.1.1.11 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-(trifluoromethyl)-benzene 
sulfonamide) (1m) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 61% yield as a white solid. M.p. 184-186 °C. TLC (9:1 DCM-MeOH, Rf: 
0.65). 1H-NMR (DMSO-d6), : 1.48 (m, 4H), 2.16 (bm, 12H), 2.81 (m, 4H), 7.49 (bs, 2H), 7.99 (m, 8H). 
13C-NMR (DMSO-d6), : 26.0, 40.8, 52.5, 54.6, 123.6 (q, J= 272.7 Hz), 126.4 (q, J= 3.7 Hz), 127.4, 
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132.2 (q, J= 32.2 Hz), 144.5. Anal. Calcd for C24H30F6N4O4S2: C, 46.75; H, 4.90; N, 9.09. Found: C, 
46.91; H, 5.11; N, 9.18. MS [ESI, m/z]: 617.1 [M+H]. 
 
4.1.1.12 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(biphenyl-sulfonamide) (1n) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 87% yield as a white solid. M.p. 183-185 °C. TLC (9:1 DCM-MeOH, Rf: 
0.59). 1H-NMR (DMSO-d6), : 1.46-1.50 (m, 4H), 2.12-2.22 (m, 12H), 3.51-3.56 (m, 4H), 7.41-7.44 (m, 
2H), 7.49-7.53 (m, 4H), 7.62 (bs, 2H), 7.71-7.75 (m, 4H), 7.84-7.89 (m, 8H). 13C-NMR (DMSO-d6), : 
26.0, 40.9, 52.5, 54.8, 127.0, 127.1, 127.3, 128.4, 129.0, 138.5, 139.2, 143.8. Anal. Calcd for 
C34H40N4O4S2: C, 64.53; H, 6.37; N, 8.85. Found: C, 64.24; H, 6.51; N, 8.78. MS [ESI, m/z]: 633.2 
[M+H]. 
 
4.1.1.13 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dinaphthalene-2-sulfonamide (1o) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 91% yield as a white solid. M.p. 216-218 °C. TLC (9:1 DCM-MeOH, Rf: 
0.67). 1H-NMR (DMSO-d6), : 1.36 (m, 4H), 1.93 (bs, 8H), 1.99 (t, J= 6.8 Hz, 4H), 2.79 (m, 4H), 7.67 
(m, 6H), 7.91 (bs, 2H), 8.10 (m, 4H), 8.22 (d, J= 8.2 Hz, 2H), 8.64 (d, J= 8.4 Hz, 2H).  13C-NMR (DMSO-
d6), : 25.8, 40.7, 52.3, 54.6, 124.4, 124.6, 126.7, 127.5, 127.7, 128.5, 128.9, 133.6, 133.8, 135.4. Anal. 
Calcd for C30H36N4O4S2: C, 62.04; H, 6.25; N, 9.65. Found: C, 61.91; H, 6.33; N, 9.63. MS [ESI, m/z]: 
581.2 [M+H]. 
 
4.1.1.14 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))diquinoline-8-sulfonamide (1p) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 76% yield as a white solid. M.p. 200-202 °C. TLC (9:1 DCM-MeOH, Rf: 
0.73). 1H-NMR (CDCl3), : 1.67 (m, 4H), 2.37 (bs, 12H), 2.95 (m, 4H), 6.79 (bs, 2H), 7.59 (dd, J1= 8.4, 
J2= 4.2, 2H), 7.68 (t, J= 7.6 Hz, 2H), 8.08 (d, J=8.0 Hz, 2H), 8.31 (d, J= 8.0 Hz, 2H), 8.46 (d, J= 7.1 Hz, 
2H), 9.04 (m, 2H). 13C-NMR (CDCl3), : 26.1, 42.4, 52.9, 56.0, 122.2, 125.7, 128.8, 131.4, 133.1, 136.0, 
136.9, 143.4, 151.1. Anal. Calcd for C28H34N6O4S2: C, 57.71; H, 5.88; N, 14.42. Found: C, 57.55; H, 
6.04; N, 14.34. MS [ESI, m/z]: 583.2 [M+H]. 
 
4.1.1.15 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dithiophene-2-sulfonamide (1q) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 83% yield as a white solid. TLC (9:1 DCM-MeOH, Rf: 0.45). M.p. 138-
140 °C. 1H-NMR (DMSO-d6), : 1.52 (m, 4H), 2.24 (m, 12H), 2.86 (m, 4H), 7.18 (dd, J1= 5.1, J2= 3.7, 
2H), 7.57 (dd, J1= 3.7, J2= 1.3, 2H), 7.79 (bs, 2H), 7.92 (dd, J1= 5.1, J2= 1.3, 2H). 13C-NMR (DMSO-
d6), : 25.8, 41.2, 52.6, 54.9, 127.6, 131.3, 132.2, 141.4. Anal. Calcd for C18H28N4O4S4: C, 43.88; H, 
5.73; N, 11.37. Found: C, 43.59; H, 5.96; N, 11.31. MS [ESI, m/z]: 493.0 [M+H]. 
 
4.1.1.16 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))dipyridine-3-sulfonamide (1r) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
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MeOH 91:9 v/v. Obtained in 63% yield as a pale yellow solid. M.p. 140-142 °C. TLC (9:1 DCM-MeOH, 
Rf: 0.52). 1H-NMR (DMSO-d6), : 1.50 (m, 4H), 2.20 (bs, 12H), 2.82 (bs, 4H), 7.65 (dd, J1= 8.0 Hz, J2= 
4.9 Hz, 2H), 7.85 (bs, 2H), 8.16 (dt, J1= 8.0 Hz, J2= 1.9 Hz, 2H), 8.82 (dd, J1= 4.9 Hz, J2= 1.9 Hz, 2H), 
8.94 (d, J= 2.2 Hz, 2H). 13C-NMR (DMSO-d6), : 26.0, 40.8, 52.5, 54.6, 124.2, 134.4, 136.8, 146.9, 
152.9. Anal. Calcd for C20H30N6O4S2: C, 49.77; H, 6.27; N, 17.41. Found: C, 49.55; H, 6.07; N, 17.23. 
MS [ESI, m/z]: 483.1 [M+H]. 
 
4.1.1.17 Ethyl 3-(N-(3-(4-(3-(4-carboxyphenylensulfonamido)propyl) piperazin-1-yl)propyl) 
sulfamoyl)benzoate (1s) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 41% yield as a white solid. M.p. 170-172 °C. TLC (9:1 DCM-MeOH, Rf: 
0.56). 1H-NMR (CDCl3), : 1.44 (t, J= 7.1 Hz, 6H), 1.67 (m, 4H), 2.47 (m, 12H), 3.11 (t, J= 5.6 Hz, 4H), 
4.44 (q, J= 7.1 Hz, 4H), 7.45 (bs, 2H), 7.92 (d, J= 8.5 Hz, 4H), 8.19 (d, J= 8.5 Hz, 4H). 
13C-NMR (CDCl3), : 14.2, 23.8, 44.3, 53.0, 57.9, 61.6, 126.8, 130.2, 133.9, 144.1, 165.2. Anal. Calcd 
for C28H40N4O8S2: C, 53.83; H, 6.45; N, 8.97. Found: C, 53.69; H, 6.71; N, 8.76. MS [ESI, m/z]: 625.2 
[M+H]. 
 
4.1.1.18 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(2-chlorobenzene-sulfonamide) (1u) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 98:2 v/v. Obtained in 80% yield as a white solid. M.p. 162-164 °C. TLC (9:1 DCM-MeOH, Rf: 
0.79). 1H-NMR (DMSO-d6), : 1.49 (m, 4H), 2.17 (m, 12H), 2.85 (m, 4H), 7.54 (td, J1= 7.4 Hz, J2= 1.5 
Hz, 2H), 7.65 (m, 4H), 7.88 (t, J= 5.1 Hz, 2H), 7.96 (dd, J1= 7.9 Hz, J2= 1.3 Hz, 2H). 13C-NMR (DMSO-
d6), : 25.7, 41.0, 52.5, 54.9, 127.6, 130.5, 130.5, 131.7, 133.9, 137.8. Anal. Calcd for C22H30Cl2N4O4S2: 
C, 48.08; H, 5.50; N, 10.20. Found: C, 48.27; H, 5.34; N, 10.32. MS [ESI, m/z]: 549.1, 551.1 [M+H]. 
 
4.1.1.19 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-chlorobenzene sulfonamide) (8a) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 95:5 v/v. Obtained in 45% yield as a white solid. M.p. 218-220 °C. TLC (9:1 DCM-MeOH, Rf: 
0.66). 1H-NMR (CDCl3), : 2.17, (bs, 8H), 2.43 (t, J= 5.5, 4H), 3.08 (m, 4H), 5.14 (bs, 2H), 7.51 (d, J= 
8.5 Hz, 4H), 7.82 (d, J= 8.5 Hz, 4H). 13C-NMR (DMSO-d6), : 40.9, 52.8, 54.9, 128.6, 129.7, 137.9, 
139.8. Anal. Calcd for C20H26Cl2N4O4S2: C, 46.06; H, 5.03; N, 10.74. Found: C, 46.23; H, 5.31; N, 10.87. 
MS [ESI, m/z]: 521.0, 523.0 [M+H]. 
 
4.1.1.20 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))dibenzenesulfonamide (8b) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 53% yield as a white solid. M.p. 158-160 °C. TLC (9:1 DCM-MeOH, Rf: 
0.40). 1H-NMR (CDCl3), : 2.17, (s, 8H, H-3’), 2.39 (t, J= 5.8, 4H, H-2’), 3.00 (m, 4H, H-1’), 5.13 (bs, 
2H, NH), 7.53 (m, 4H, H-3), 7.60 (tt, J1= 7.3 Hz, J2= 2.1 Hz, 2H, H-4), 7.88 (m, 4H, H-2). 13C-NMR 
(CDCl3), : 39.1, 52.2, 55.4, 127.0, 129.0, 132.6, 139.6. Anal. Calcd for C20H28N4O4S2: C, 53.08; H, 
6.24; N, 12.38. Found: C, 52.89; H, 6.53; N, 12.32. MS [ESI, m/z]: 453.1 [M+H]. 
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4.1.1.21 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-methylbenzene-sulfonamide) (8c) 
[37] 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 98:2 v/v. Obtained in 89% yield as a white solid. M.p. 182-184°C (lit. 185-187°C) [34]. TLC (9:1 
DCM-MeOH, Rf: 0.59). 1H-NMR (CDCl3), : 2.24, (bs, 8H), 2.39 (t, J= 5.7, 4H), 2.45 (s, 6H), 2.98 (m, 
4H), 5.10 (bs, 2H), 7.32 (d, J= 8.2 Hz, 4H), 7.57 (d, J= 8.2 Hz, 4H). 13C-NMR (DMSO-d6), : 20.9, 40.0, 
52.4, 56.7, 126.4, 129.5, 137.6, 142.4. Anal. Calcd for C22H32N4O4S2: C, 54.98; H, 6.71; N, 11.66. Found: 
C, 54.93; H, 6.95; N, 11.64. MS [ESI, m/z]: 481.1 [M+H]. 
 
4.1.1.22 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-methoxy-benzenesulfonamide) (8d) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 87% yield as a white solid. M.p. 170-172 °C. TLC (9:1 DCM-MeOH, Rf: 
0.45). 1H-NMR (DMSO-d6), : 1.45 (t, J= 5.4, 4H), 2.24, (bm, 8H), 2.71-2.75 (m, 4H), 3.89 (s, 6H), 7.09 
(d, J= 8.8 Hz, 4H), 7.41 (t, J= 5.5 Hz, 2H), 7.81 (d, J= 8.8 Hz, 4H). 13C-NMR (CDCl3), : 39.1, 52.3, 
55.4, 55.6, 114.1, 129.2, 131.1, 162.8. Anal. Calcd for C22H32N4O6S2: C, 51.54; H, 6.29; N, 10.93. Found: 
C, 51.39; H, 6.47; N, 10.84. MS [ESI, m/z]: 513.1 [M+H]. 
 
4.1.1.23 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-nitrobenzene-sulfonamide) (8e) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 63% yield as a pale yellow solid. M.p. 212-214 °C. TLC (9:1 DCM-MeOH, 
Rf: 0.68). 1H-NMR (DMSO-d6), : 2.18, (bs, 8H), 2.55 (t, J= 6.6, 4H), 2.98 (t, J= 6.6 Hz, 4H), 7.92 (bs, 
2H), 8.05 (d, J= 8.8 Hz, 4H), 8.40 (d, J= 8.8 Hz, 4H). 13C-NMR (DMSO-d6), : 40.0, 52.3, 56.8, 124.4, 
127.9, 146.4, 149.4. Anal. Calcd for C20H26N6O8S2: C, 44.27; H, 4.83; N, 15.49. Found: C, 44.17; H, 
4.66; N, 15.27. MS [ESI, m/z]: 543.0 [M+H]. 
 
4.1.1.24 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(3,4-dimethoxy-benzenesulfonamide) 
(8f) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 74% yield as a white solid. M.p. 152-154 °C. TLC (9:1 DCM-MeOH, Rf: 
0.53). 1H-NMR (CDCl3), : 2.26, (bs, 8H), 2.40 (t, J= 5.6, 4H), 2.99 (m, 4H), 3.94 (s, 6H), 3.96 (s, 6H), 
5.11 (bs, 2H), 6.94 (m, 2H), 7.34 (m, 2H), 7.49 (m, 2H). 13C-NMR (CDCl3), : 39.1, 52.3, 56.2, 56.3, 
56.4, 109.7, 110.5, 121.0, 131.2, 149.1, 152.5. Anal. Calcd for C24H36N4O8S2: C, 50.33; H, 6.34; N, 9.78. 
Found: C, 50.19; H, 6.50; N, 9.62. MS [ESI, m/z]: 573.1 [M+H]. 
 
4.1.1.25 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(2,5-dimethoxy-benzenesulfonamide) 
(8g) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 95:5 v/v. Obtained in 77% yield as a white solid. M.p. 176-178 °C. TLC (9:1 DCM-MeOH, Rf: 
0.47). 1H-NMR (CDCl3), : 2.31, (bs, 8H), 2.42 (t, J= 5.6, 4H), 2.98 (m, 4H), 3.83 (s, 6H), 3.92 (s, 6H), 
5.58 (t, J= 4.9 Hz, 2H), 6.96 (d, J= 9.1 Hz, 2H), 7.08 (dd, J1=9.1 Hz, J2= 3.1 Hz, 2H), 7.47 (d, J= 3.1 Hz, 
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2H). 13C-NMR (CDCl3), : 39.8, 52.6, 56.0, 56.1, 57.1, 113.7, 114.8, 120.3, 127.8, 150.2, 153.4. Anal. 
Calcd for C24H36N4O8S2: C, 50.33; H, 6.34; N, 9.78. Found: C, 50.26; H, 6.65; N, 9.76. MS [ESI, m/z]: 
573.1 [M+H]. 
 
4.1.1.26 N,N’-(2,2’-(Piperazine-1,4-diyl)bis(ethane-2,1-diyl))dinaphthalene-2-sulfonamide (8h) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 82% yield as a white solid. M.p. 176-178 °C. TLC (9:1 DCM-MeOH, Rf: 
0.56). 1H-NMR (CDCl3), : 2.18, (bs, 8H), 2.37 (t, J= 5.8, 4H), 3.01 (m, 4H), 5.22 (bs, 2H), 7.66 (m, 
4H), 7.82 (dd, J1= 8.8 Hz, J2= 1.8 Hz, 2H), 7.92 (d, J= 8.1 Hz, 2H), 7.97 (m, 4H), 8.45 (s, 2H). 
13C-NMR (CDCl3), : 39.2, 52.3, 55.5, 122.2, 127.7, 127.9, 128.6, 128.8, 129.2, 129.4, 131.9, 134.7, 
137.3. Anal. Calcd for C28H32N4O4S2: C, 60.85; H, 5.84; N, 10.14. Found: C, 60.71; H, 6.03; N, 10.06. 
MS [ESI, m/z]: 553.1 [M+H]. 
 
4.1.2 Synthesis of 3-(N-(3-(4-(3-(4-Carboxyphenylensulfonamido)propyl)piperazin-1-yl)-propyl)-
sulfamoyl) benzoic acid (1t) 
Compound 1s (0.15 g, 0.3 mmol) was dissolved 3 mL of THF. LiOH monohydrate (0.07 g, 1.7 mmol) 
was dissolved in 4 mL of distilled water and added to the THF solution. The reaction was stirred o.n. at 
80 °C. The organic solvent was then removed at reduced pressure and the water residue was acidified to 
pH 5 with 1M HCl solution. The resulting precipitate was filtered, washed with water and dried under 
vacuum to afford a pure white solid in 88% yield. M.p. > 300 °C. 1H-NMR (D2O), : 1.48 (m, 4H), 2.15 
(t, J= 7.8 Hz, 4H), 2.31 (bm, 8H), 2.69 (t, J= 7.1 Hz, 4H), 7.72 (d, J= 8.1 Hz, 4H), 7.88 (d, J= 8.1 Hz, 
4H). 13C-NMR (D2O), : 27.8, 43.5, 51.5, 55.6, 126.2, 129.1, 138.7, 145.2, 174.5. Anal. Calcd for 
C24H32N4O8S2: C, 50.69; H, 5.67; N, 9.85. Found: C, 50.53; H, 5.45; N, 9.71. MS [ESI, m/z]: 591.1 
[M+Na]. 
 
4.1.3 General method for the preparation of N,N’-(piperazine-1,4-diyl)bis(3-oxopropane-)diaryl 
sulfonamides 11 
The different 3-arylsulfonylamino propionic acid 10 (1.3 mmol), TBTU (0.45 g, 1.4 mmol) and HOBt 
(0.19 g, 1.4 mmol) were suspended in anhydrous THF (9 mL) at r.t. DiPEA (0.7 mL, 4.2 mmol) was then 
added to the reaction mixture, followed by piperazine (41) (0.05 g, 0.6 mmol). The reaction mixture was 
left stirring at r.t. for 4 h. The organic solvent was then removed at reduced pressure and the residue was 
suspended in EtOAc (100 mL). The organic layer was washed with saturated NaHCO3 solution (2 x 70 
mL), then with saturated NH4Cl solution (2 x 70 mL) and finally with brine (70 mL). The organic solvent 
was removed under vacuum after drying over MgSO4. The crude residue was purified by flash column 
chromatography. 
 
4.1.3.1 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(4-chlorobenzene-sulfonamide) 
(11a) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 98:2 v/v. Obtained in 41% yield as a white solid. M.p. 206-208 °C. TLC (9:1 DCM-MeOH, Rf: 
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0.76). 1H-NMR (CDCl3), : 2.62 (t, J= 5.2 Hz, 4H), 3.33 (m, 4H), 3.43 (m, 4H), 3.56 (m, 4H), 7.1 (bs, 
2H), 7.52 (d, J= 8.5 Hz, 4H), 7.83 (d, J= 8.5 Hz, 4H). 13C-NMR (DMSO-d6), : 32.5, 38.8, 40.6, 40.9, 
44.3, 44.6, 128.4, 129.3, 137.2, 139.2, 168.6. Anal. Calcd for C22H26Cl2N4O6S2: C, 45.75; H, 4.54; N, 
9.70. Found: C, 45.61; H, 4.81; N, 9.52. MS [ESI, m/z]: 598.9, 600.9 [M+Na]. 
 
4.1.3.2 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(4-methoxybenzene-
sulfonamide) (11d) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 98:2 v/v. Obtained in 46% yield as a white solid. M.p. 178-180 °C. TLC (9:1 DCM-MeOH, Rf: 
0.65). 1H-NMR (CDCl3), : 2.59 (t, J= 5.6 Hz, 4H), 3.23 (m, 4H), 3.42 (m, 4H), 3.60 (m, 4H), 3.89 (s, 
6H), 5.42 (bs, 2H), 7.00 (d, J= 8.8 Hz, 4H), 7.82 (d, J= 8.8 Hz, 4H). 13C-NMR (CDCl3), : 33.0, 33.1, 
39.0, 39.1, 41.2, 44.7, 44.9, 55.6, 114.3, 129.1, 131.7, 162.8, 168.8. Anal. Calcd for C24H32N4O8S2: C, 
50.69; H, 5.67; N, 9.85. Found: C, 50.67; H, 5.92; N, 9.76. MS [ESI, m/z]: 591.1 [M+Na]. 
 
4.1.3.3 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(3,4-dimethoxy-benzene 
sulfonamide) (11f) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 98:2 v/v. Obtained in 47% yield as a white solid. M.p. 102-104 °C. TLC (9:1 DCM-MeOH, Rf: 
0.65). 1H-NMR (CDCl3), : 2.80 (bs, 4H), 3.21 (m, 4H), 3.55 (m, 4H), 3.95 (m, 12H), 4.04 (bs, 4H), 5.25 
(bs, 1H), 5.54 (bs, 1H), 6.97 (m, 2H), 7.33 (m, 2H), 7.49 (m, 2H). 13C-NMR (CDCl3), : 33.0, 33.2, 38.8, 
39.0, 41.1, 41.3, 44.9, 45.1, 56.2, 56.3, 56.4, 56.5, 109.6, 109.7, 110.6, 110.7, 120.8, 120.9, 129.9, 131.6, 
149.2, 149.5, 152.0, 152.7, 169.8, 171.8. Anal. Calcd for C26H36N4O10S2: C, 49.67; H, 5.77; N, 8.91. 
Found: C, 49.51; H, 6.03; N, 8.80. MS [ESI, m/z]: 651.1 [M+Na]. 
 
4.1.3.4 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))bis(2,5-dimethoxy-benzene 
sulfonamide) (11g) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 52% yield as a white solid. M.p. 90-92 °C. TLC (9:1 DCM-MeOH, Rf: 
0.63). 1H-NMR (CDCl3), : 2.55 (t, J= 6.0 Hz, 4H), 3.22 (m, 4H), 3.37 (m, 4H), 3.60 (m, 4H), 3.84 (s, 
6H), 3.97 (s, 6H), 5.92 (t, J= 6.1 Hz, 2H), 7.00 (d, J= 9.0 Hz, 2H), 7.09 (dd, J1= 9.0 Hz, J2= 3.0 Hz, 2H), 
7.46 (d, J= 3.0 Hz, 2H). 13C-NMR (DMSO-d6), : 32.2, 40.5, 40.8, 44.2, 44.4, 55.7, 56.5, 114.2, 114.3, 
119.5, 128.2, 150.1, 152.3, 168.9. Anal. Calcd for C26H36N4O10S2: C, 49.67; H, 5.77; N, 8.91. Found: C, 
49.61; H, 5.93; N, 8.89. MS [ESI, m/z]: 651.1 [M+Na]. 
 
4.1.3.5 N,N’-(3,3’-(Piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))dinaphthalene-2-sulfonamide (11h) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 54% yield as a white solid. M.p. 228-230 °C. TLC (9:1 DCM-MeOH, Rf: 
0.79). 1H-NMR (CDCl3), : 2.55 (m, 4H), 3.28 (m, 8H), 3.52 (m, 4H), 5.61 (bs, 2H), 7.66 (m, 4H), 7.86 
(dd, J1= 8.7 Hz, J2= 1.7 Hz, 2H), 7.93 (d, J= 7.9 Hz, 2H), 7.99 (m, 4H), 8.45 (s, 2H). 13C-NMR (DMSO-
d6), : 32.5, 38.9, 40.5, 40.8, 44.2, 44.4, 122.2, 127.3, 127.5, 127.7, 128.6, 129.1, 129.3, 131.6, 134.11, 
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137.3, 168.5. Anal. Calcd for C30H32N4O6S2: C, 59.19; H, 5.30; N, 9.20. Found: C, 58.84; H, 5.61; N, 
9.96. MS [ESI, m/z]: 631.0 [M+Na]. 
 
4.1.4 Synthesis of {4-[4-(4-tert-Butoxycarbonylamino-butyl)-piperazin-1-yl]-butyl}-carbamic acid 
tert-butyl ester (16) 
Piperazine (0.17 g, 2.1 mmol) and NaHCO3 (0.38, 4.5 mmol) were suspended in 3 mL of absolute ethanol 
and added dropwise of 79 (1.21 g, 4.5 mmol) diluted in 5 mL of ethanol. The reaction mixture was stirred 
under reflux for 24 h. The solvent was evaporated under vacuum, and the residue was suspended in DCM 
(30 mL) and washed with saturated NaHCO3 solution (2 x 30 mL) and brine (30 mL). The organic phase 
was evaporated at reduced pressure after drying over MgSO4 to give a yellow solid in 70% yield. 1H-
NMR (CDCl3), : 1.37 (m, 18 H), 1.63 (m, 8H), 2.32 (bs, 4H), 2.56 (bs, 8H), 3.33 (t, J= 5.3 Hz, 4H), 
5.56 (bs, 2H). 13C-NMR (CDCl3), : 24.4, 25.7, 28.4, 28.5, 40.5, 53.0, 58.0, 78.8, 156.0. MS [ESI, m/z]: 
397.3 [M+H]. 
 
4.1.5 N,N’-(4,4’-(Piperazine-1,4-diyl)bis(butane-4,1-diyl))bis(4-chlorobenzene-sulfonamide) (17) 
Compound 16 (0.63 g, 1.5 mmol) was dissolved at 0 °C in a mixture of 2 mL of TFA and 0.2 mL of 
distilled water. The reaction mixture was left stirring at r.t for 30 min., then the volume was reduced 
under vacuum and the remaining suspension was poured dropwise into 5 mL of ice-cooled diethyl ether. 
The resulting white precipitate was left in the fridge o.n. before being filtered and washed with cold 
diethyl ether. The white solid was suspended with 4-chlorobenzenesulfonyl chloride (2a) (0.63 g, 3.0 
mmol) in 7 mL of anhydrous DCM; the resulting mixture was treated dropwise with triethylamine (1.3 
mL, 9.5 mmol) under ice-cooling and stirred for 1 h at r.t. The reaction mixture was then diluted with 
DCM and washed with water (2 x 30 mL) and brine (30 mL). The organic solvent was removed under 
vacuum after drying over MgSO4 and the crude residue was purified by flash column chromatography 
eluting with DCM-MeOH 100:0 v/v increasing to DCM-MeOH 91:9 v/v to give a white solid in 15% 
yield. M.p. 182-184 °C. TLC (9:1 DCM-MeOH, Rf: 0.64). 1H-NMR (CDCl3), : 1.63 (m, 8H), 2.50 (bm, 
4H), 2.77 (bm, 8H), 2.96 (t, J= 5.3 Hz, 4H), 7.49 (d, J= 8.6 Hz, 4H), 7.81 (d, J= 8.6 Hz, 4H). 13C-NMR 
(CDCl3), : 24.1, 28.2, 42.8, 51.8, 57.7, 128.4, 129.2, 138.7, 139.2. Anal. Calcd for C24H34 Cl2N4O4S2: 
C, 49.91; H, 5.93; N, 9.70. Found: C, 49.67; H, 6.11; N, 9.61. MS [ESI, m/z]: 577.1, 579.1 [M+H]. 
 
4.1.6 Synthesis of N,N’-(3,3’-(piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(4-chlorobenzamide) 
(20) [38] 
A mixture of 19 (0.5 g, 1.8 mmol), piperazine (0.07 g, 0.8 mmol) and triethylamine (0.24 mL, 1.7 mmol) 
in 7 mL of anhydrous THF was stirred under nitrogen atmosphere for 48 h at r.t. The reaction mixture 
was then diluted with DCM (20 mL), washed with saturated NaHCO3 solution (2 x 30 mL) and brine (30 
mL) and dried over MgSO4. The organic solvent was removed under vacuum and the crude residue was 
purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 91:9 v/v to give a white solid in 36% yield. M.p. 180-182 °C. TLC (9:1 DCM-MeOH, Rf: 0.63). 
1H-NMR (CDCl3), : 1.82 (m, 4H), 2.56 (m, 12H), 3.59 (m, 4H), 7.42 (d, J= 8.5 Hz, 4H), 7.78 (d, J= 8.5 
Hz, 4H), 8.05 (bs, 2H). 13C-NMR (DMSO-d6), : 26.1, 37.9, 52.7, 55.6, 128.2, 129.0, 133.3, 135.7, 164.9. 
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Anal. Calcd for C24H30Cl2N4O2: C, 60.38; H, 6.33; N, 11.74. Found: C, 60.58; H, 6.51; N, 11.90. MS 
[ESI, m/z]: 477.1, 479.1 [M+H]. 
 
4.1.7 Synthesis of N,N’-(2,2’-(1,4-phenylenebis(azanediyl))bis(ethane-2,1-diyl))bis(4-
chlorobenzenesulfonamide) (21) 
A mixture of 7a (1.05 g, 3.5 mmol), 4-phenylendiamine (0.16 g, 1.5 mmol) and triethylamine (0.47 mL, 
3.4 mmol) in 13 mL of anhydrous THF was stirred under nitrogen atmosphere for 72 h at r.t. The reaction 
mixture was then diluted with DCM (35 mL), washed with saturated NaHCO3 solution (2 x 30 mL) and 
brine (30 mL) and dried over MgSO4. The organic solvent was removed under vacuum and the crude 
residue was purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing 
to n-hexane-EtOAc 20:80 v/v to afford a light brown solid in 17% yield. M.p. 162-164 °C. TLC (8:2 
EtOAc-nhexane, Rf: 0.46). 1H-NMR (DMSO-d6), : 2.87 (t, J= 6.5 Hz, 4H), 2.97 (m, 4H), 4.70 (t, J= 
6.1 Hz, 2H), 6.32 (s, 4H), 7.65 (d, J= 8.6 Hz, 4H), 7.79 (d, J= 8.6 Hz, 4H), 7.81 (bs, 2H). 13C-NMR 
(DMSO-d6), : 41.8, 43.6, 113.7, 128.3, 129.3, 137.2, 139.3, 139.6. Anal. Calcd for C22H24Cl2N4O4S2: 
C, 48.62; H, 4.45; N, 10.31. Found: C, 48.81; H, 4.39; N, 10.38. MS [ESI, m/z]: 543.0, 545.0 [M+H]. 
 
4.1.8 General method for the preparation of unsymmetrical sulfonamides 23-36 
A mixture of the different N-(3-piperazin-1-yl-propyl)-arylsulfonamide 22 (1.0 mmol), N-(3-
bromopropyl)arylsulfonamide 3 or N-(2-bromoethyl)arylsulfonamide 2 (1.5 mmol) and NaHCO3 (0.16 
g, 2 mmol) in absolute ethanol (7 mL) was stirred under reflux for 24 h. The solvent was evaporated 
under reduced pressure and the crude residue was purified by flash column chromatography. 
 
4.1.8.1 N-{3-[4-(3-Benzenesulfonylamino-propyl)-piperazin-1-yl]-propyl}-4-chloro-benzene 
sulfonamide (23) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 58% yield as a white solid. M.p. 128-130 °C. TLC (9:1 DCM-MeOH, Rf: 
0.59). 1H-NMR (DMSO-d6), : 1.44-1.51 (m, 4H), 2.11-2.26 (m, 12H), 2.74-2.79 (m, 4H), 7.56-7.62 (m, 
3H), 7.61-7.64 (m, 1H), 7.66-7.70 (m, 3H), 7.78 (d, J= 8.3 Hz, 2H). 13C-NMR (DMSO-d6), : 26.0, 26.1, 
40.8, 40.9, 52.5, 54.7, 54.8, 126.4, 128.4, 129.1, 129.3, 132.2, 137.1, 139.3, 140.5. Anal. Calcd for 
C22H31ClN4O4S2: C, 51.30; H, 6.07; N, 10.88. Found: C, 51.19; H, 6.35; N, 10.67. MS [ESI, m/z]: 515.1, 
517.1 [M+H]. 
 
4.1.8.2 4-Chloro-N-(3-(4-(3-(4-methylbenzenesulfonylamido)propyl)-piperazin-1-yl)-propyl)benzene 
sulfonamide (24) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 86% yield as a white solid. M.p. 172-174 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.57). 1H-NMR (DMSO-d6), : 1.43-1.51 (m, 4H), 2.10-2.28 (m, 12H), 2.38 (s, 3H), 2.69-2.81 (m, 
4H), 7.39 (d, J= 8.1 Hz, 2H),7.48 (t, J= 5.6 Hz, 1H), 7.64-7.71 (m, 5H), 7.79 (d, J= 8.7 Hz, 2H). 13C-
NMR (DMSO-d6), : 20.9, 26.0, 40.8, 40.9, 52.5, 54.7, 54.8, 126.5, 128.4, 129.3, 129.5, 137.1, 137.6, 
139.4, 142.4. Anal. Calcd for C23H33ClN4O4S2: C, 52.21; H, 6.29; N, 10.59. Found: C, 52.09; H, 5.94; 
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N, 10.58. MS [ESI, m/z]: 529.1, 531.1 [M+H]. 
 
4.1.8.3 4-tert-Butyl-N-(3-(4-(3-(4-chlorophenylsulfonylamido)propyl)-piperazin-1-yl)-propyl)benzene 
sulfonamide (25) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 60% yield as a white solid. M.p. 130-132 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.44).  1H-NMR (DMSO-d6), : 1.30 (s, 9H), 1.41-1.53 (m, 4H), 2.11-2.35 (m, 12H), 2.72-2.80 (m, 
4H), 7.49 (t, J= 5.5 Hz, 1H), 7.60 (d, J= 8.5 Hz, 2H), 7.65-7.72 (m, 5H), 7.78 (d, J= 8.5 Hz, 2H). 13C-
NMR (DMSO-d6), : 26.0, 30.7, 34.7, 40.8, 40.9, 52.5, 52.6, 54.7, 54.8, 125.9, 126.3, 128.4, 129.3, 
137.1, 137.7, 139.4, 155.1. Anal. Calcd for C26H39ClN4O4S2: C, 54.67; H, 6.88; N, 9.80. Found: C, 54.51; 
H, 6.49; N, 9.61. MS [ESI, m/z]: 571.2, 573.2 [M+H]. 
 
4.1.8.4 4-Chloro-N-(3-(4-(3-(4-(trifluoromethyl)phenylsulfonylamido)propyl)-piperazin-1-yl)-propyl) 
benzenesulfonamide (26) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 85% yield as a white solid. M.p. 158-160 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.61). 1H-NMR (DMSO-d6), : 1.44-1.51 (m, 4H), 2.11-2.27 (m, 12H), 2.74-2.83 (m, 4H), 7.67 (d, 
J= 8.5 Hz, 2H), 7.69 (bs, 1H), 7.78 (d, J= 8.5 Hz, 2H), 7.86 (bs, 1H), 7.94-8.03 (m, 4H). 13C-NMR 
(DMSO-d6), : 26.0, 40.7, 40.8, 52.5, 54.6, 54.7, 126.4 (q, J= 3.7 Hz), 127.4, 128.4, 129.2, 131.8, 131.9, 
137.1, 139.4, 144.5. Anal. Calcd for C23H30ClF3N4O4S2: C, 47.38; H, 5.19; N, 9.61. Found: C, 47.32; H, 
5.17; N, 9.48. MS [ESI, m/z]: 583.1, 585.1 [M+H]. 
 
4.1.8.5 N-(3-(4-(3-(4-Chlorophenylsulfonylamido)propyl)-piperazin-1-yl)-propyl)biphenyl-4-
sulfonamide (27) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 71% yield as a white solid. M.p. 138-140 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.63). 1H-NMR (DMSO-d6), : 1.42-1.54 (m, 4H), 2.15-2.31 (m, 12H), 2.72-2.81 (m, 4H), 7.44 (t, 
J= 5.7 Hz, 1H), 7.50-7.54 (m, 2H), 7.62 (t, J= 5.7 Hz, 1H), 7.65-7.79 (m, 3H), 7.74 (d, J= 7.1 Hz, 2H), 
7.78 (d, J= 8.6 Hz, 2H), 7.85 (d, J= 8.6 Hz, 2H), 7.89 (d, J= 8.6 Hz, 2H). 13C-NMR (DMSO-d6), : 26.0, 
26.1, 40.8, 40.9, 52.5, 54.7, 54.8, 127.0, 127.1, 127.3, 128.4, 129.0, 129.3, 137.1, 138.5, 139.2, 139.3, 
143.8. Anal. Calcd for C28H35ClN4O4S2: C, 56.89; H, 5.97; N, 9.48. Found: C, 56.73; H, 6.08; N, 9.30. 
MS [ESI, m/z]: 591.1, 593.1 [M+H]. 
 
4.1.8.6 4-tert-Butyl-N-(3-(4-(3-(phenylsulfonylamido)propyl)-piperazin-1-yl)-propyl)benzene 
sulfonamide (28) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 54% yield as a white solid. M.p. 134-136 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.55). 1H-NMR (DMSO-d6), : 1.30 (s, 9H), 1.43-1.49 (m, 4H), 2.11-2.26 (m, 12H), 2.72-2.78 (m, 
4H), 7.49 (t, J= 5.6 Hz, 1H), 7.58-7.62 (m, 5H), 7.66-7.69 (m, 1H), 7.70 (d, J= 8.5 Hz, 2H), 7.78 (d, J= 
7.8 Hz, 2H). 13C-NMR (DMSO-d6), : 26.0, 26.1, 30.7, 34.7, 40.8, 40.9, 52.5, 52.6, 54.8, 54.9, 125.9, 
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126.3, 126.4, 129.1, 132.2, 137.6, 140.5, 155.2. Anal. Calcd for C26H40N4O4S2: C, 58.18; H, 7.51; N, 
10.44. Found: C, 58.35; H, 7.46; N, 10.47. MS [ESI, m/z]: 537.2 [M+H]. 
 
4.1.8.7 4-tert-Butyl-N-(3-(4-(3-(4-methylphenylsulfonylamido)propyl)-piperazin-1-yl)-propyl)benzene 
sulfonamide (29) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 83% yield as a white solid. M.p. 155-157 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.64). 1H-NMR (DMSO-d6), : 1.30 (s, 9H), 1.43-1.49 (m, 4H), 2.09-2.24 (m, 12H), 2.38 (s, 3H), 
2.70-2.78 (m, 4H), 7.39 (d, J= 8.1 Hz, 2H), 7.49 (bs, 2H), 7.60 (d, J= 8.5 Hz, 2H), 7.66 (d, J= 8.1 Hz, 
2H), 7.70 (d, J= 8.5 Hz, 2H). 13C-NMR (DMSO-d6), : 20.9, 26.0, 30.7, 34.7, 40.8, 40.9, 52.5, 52.6, 54.8, 
54.9, 125.9, 126.3, 126.5, 129.5, 137.6, 137.7, 142.4, 155.1. Anal. Calcd for C27H42N4O4S2: C, 58.88; H, 
7.69; N, 10.17. Found: C, 59.07; H, 7.92; N, 10.23. MS [ESI, m/z]: 573.2 [M+Na]. 
 
4.1.8.8 4-tert-Butyl-N-(3-(4-(3-(4-(trifluoromethyl)phenylsulfonylamido)propyl)-piperazin-1-yl)-
propyl)benzenesulfonamide (30) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 95:5 v/v. Obtained in 70% yield as a white solid. M.p. 156-158 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.76). 1H-NMR (DMSO-d6), : 1.30 (s, 9H), 1.42-1.51 (m, 4H), 2.09-2.26 (m, 12H), 2.73-2.77 (m, 
2H), 2.78-2.82 (m, 2H), 7.49 (t, J= 5.5 Hz, 1H), 7.60 (d, J= 8.4 Hz, 2H), 7.70 (d, J= 8.4 Hz, 2H), 7.86 
(bs, 1H), 7.97-9.01 (m, 4H). 13C-NMR (DMSO-d6), : 26.0, 30.7, 34.7, 40.8, 40.9, 52.5, 52.6, 54.6, 54.8, 
125.9, 126.3, 126.4, 126.5, 127.4, 132.2, 137.7, 144.5, 155.1. Anal. Calcd for C27H39F3N4O4S2: C, 53.62; 
H, 6.50; N, 9.26. Found: C, 53.46; H, 6.71; N, 9.25. MS [ESI, m/z]: 605.2 [M+H]. 
 
4.1.8.9 N-(3-(4-(3-(4-tert-Butylphenylsulfonylamido)propyl)-piperazin-1-yl)-propyl) biphenyl-4-
sulfonamide (31) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 58% yield as a white solid. M.p. 146-148 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.62). 1H-NMR (DMSO-d6), : 1.29 (s, 9H), 1.41-1.53 (m, 4H), 2.07-2.25 (m, 12H), 2.71-2.83 (m, 
4H), 7.44 (t, J= 7.5 Hz, 1H), 7.47-7.53 (m, 3H), 7.58-7.64 (m, 3H), 7.70 (d, J= 8.5 Hz, 2H), 7.74 (d, J= 
7.2 Hz, 2H), 7.85 (d, J= 8.5 Hz, 2H), 7.89 (d, J= 8.5 Hz, 2H). 13C-NMR (DMSO-d6), : 26.0, 26.1, 30.7, 
34.7, 40.8, 40.9, 52.5, 52.6, 54.8, 125.9, 126.3, 127.0, 127.2, 127.3, 128.4, 129.1, 137.7, 138.5, 139.2, 
143.7, 155.1. Anal. Calcd for C32H44N4O4S2: C, 62.71; H, 7.24; N, 9.14. Found: C, 62.69; H, 7.32; N, 
9.09. MS [ESI, m/z]: 613.2 [M+H]. 
 
4.1.8.10 4-Methyl-N-(3-(4-(3-(phenylsulfonylamido)propyl)-piperazin-1-yl)-propyl)benzene 
sulfonamide (32) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 95:5 v/v. Obtained in 52% yield as a white solid. M.p. 137-139 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.65). 1H-NMR (DMSO-d6), : 1.43-1.51 (m, 4H), 2.13-2.26 (m, 12H), 2.38 (s, 3H), 2.70-2.79 (m, 
4H), 7.39 (d, J= 8.1 Hz, 2H), 7.48 (t, J= 5.4 Hz, 1H), 7.56-7.62 (m, 3H), 7.66 (d, J= 8.1 Hz, 2H), 7.61-
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7.64 (m, 1H), 7.78 (d, J= 7.5 Hz, 2H). 13C-NMR (DMSO-d6), : 20.9, 26.0, 26.1, 40.9, 52.6, 54.8, 126.4, 
126.5, 129.2, 129.5, 132.2, 137.6, 140.5, 142.4. Anal. Calcd for C23H34N4O4S2: C, 55.84; H, 6.93; N, 
11.33. Found: C, 55.73; H, 7.18; N, 11.20. MS [ESI, m/z]: 495.2 [M+H]. 
 
4.1.8.11 N-(3-(4-(3-(4-Methylphenylsulfonylamido)propyl)-piperazin-1-yl)-propyl)biphenyl-4-
sulfonamide (33) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 67% yield as a white solid. M.p. 134-136 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.58). 1H-NMR (DMSO-d6), : 1.42-1.54 (m, 4H), 2.13-2.25 (m, 12H), 2.37 (s, 3H), 2.69-2.74 (m, 
2H), 2.78-2.83 (m, 2H), 7.38 (d, J= 8.1 Hz, 2H), 7.44 (t, J= 7.3 Hz, 1H), 7.47 (t, J= 5.5 Hz, 1H), 7.49-
7.53 (m, 2H), 7.63 (t, J= 5.5 Hz, 1H), 7.66 (d, J= 8.2 Hz, 2H), 7.72-7.75 (m, 2H), 7.86 (d, J= 8.5 Hz, 
2H), 7.89 (d, J= 8.5 Hz, 2H). 13C-NMR (DMSO-d6), : 20.9, 26.0, 26.1, 40.9, 52.6, 54.8, 54.9, 126.5, 
127.0, 127.2, 127.3, 128.4, 129.1, 129.6, 137.6, 138.5, 139.3, 142.5, 143.8. Anal. Calcd for 
C29H38N4O4S2: C, 61.03; H, 6.71; N, 9.82. Found: C, 60.86; H, 6.52; N, 9.74. MS [ESI, m/z]: 571.2 
[M+H]. 
 
4.1.8.12 N-(3-(4-(3-(Phenylsulfonamido)propyl)-piperazin-1-yl)-propyl)biphenyl-4-sulfonamide (34) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 71% yield as a white solid. M.p. 124-126 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.47). 1H-NMR (DMSO-d6), : 1.42-1.54 (m, 4H), 2.11-2.25 (m, 12H), 2.73-2.77 (m, 2H), 2.78-2.82 
(m, 2H), 7.44 (t, J= 7.3 Hz, 1H), 7.50-7.53 (m, 2H), 7.56-7.61 (m, 3H), 7.61-7.66 (m, 2H), 7.70 (d, J= 
7.4 Hz, 2H), 7.77-7.79 (m, 2H), 7.85 (d, J= 8.5 Hz, 2H), 7.89 (d, J= 8.5 Hz, 2H). 13C-NMR (DMSO-d6), : 26.0, 40.9, 52.5, 54.8, 54.9, 126.4, 127.0, 127.2, 127.4, 128.4, 129.0, 129.1, 132.3, 138.5, 139.3, 142.5, 
143.8. Anal. Calcd for C28H36N4O4S2: C, 60.41; H, 6.52; N, 10.06. Found: C, 60.27; H, 6.81; N, 9.87. 
MS [ESI, m/z]: 557.2 [M+H]. 
 
4.1.8.13 N-(3-(4-(3-(Phenylsulfonamido)propyl)-piperazin-1-yl)-propyl)-4-(trifluoromethyl) benzene 
sulfonamide (35) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 50% yield as a white solid. M.p. 119-121 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.72). 1H-NMR (DMSO-d6), : 1.43-1.51 (m, 4H), 2.11-2.23 (m, 12H), 2.73-2.77 (m, 2H), 2.78-2.82 
(m, 2H), 7.58-7.61 (m, 4H), 7.62-7.66 (m, 2H), 7.77-7.79 (m, 2H), 7.88 (bs, 1H), 8.00 (s, 4H). 13C-NMR 
(DMSO-d6), : 26.0, 40.8, 40.9, 52.5, 54.6, 54.8, 126.4, 126.5, 127.4, 129.1, 132.2, 132.3, 137.6, 144.5. 
Anal. Calcd for C23H31F3N4O4S2: C, 50.35; H, 5.70; N, 10.21. Found: C, 50.51; H, 5.53; N, 10.34. MS 
[ESI, m/z]: 549.2 [M+H]. 
 
4.1.8.14 4-Chloro-N-(3-(4-(2-(4-chlorophenylsulfonamido)ethyl)-piperazin-1-yl)-propyl) benzene 
sulfonamide (36a) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 72% yield as a white solid. M.p. 133-135 °C. TLC (DCM-MeOH 9:1 v/v, 
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Rf: 0.46). 1H-NMR (DMSO-d6), : 1.43-1.51 (m, 2H), 2.07-2.27 (m, 12H), 2.73-2.80 (m, 2H), 2.82-2.87 
(m, 2H), 7.58-7.73 (m, 6H), 7.76-7.83 (m, 4H). 13C-NMR (DMSO-d6), : 26.0, 40.0, 40.8, 52.4, 52.5, 
54.7, 56.7, 128.4, 128.4, 129.2, 129.3, 137.0, 137.1, 139.3, 139.6. Anal. Calcd for C21H28Cl2N4O4S2: C, 
47.10; H, 5.27; N, 10.46. Found: C, 47.23; H, 5.54; N, 10.50. MS [ESI, m/z]: 535.1, 537.1 [M+H]. 
 
4.1.8.15 N-(3-(4-(2-(Phenylsulfonamido)ethyl)-piperazin-1-yl)-propyl) benzenesulfonamide (36b) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 47% yield as a white solid. M.p. 135-137 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.69). 1H-NMR (DMSO-d6), : 1.43-1.49 (m, 2H), 2.14-2.28 (m, 12H), 2.73-2.78 (m, 2H), 2.81-2.86 
(m, 2H), 7.49 (bs, 1H), 7.55-7.62 (m, 5H), 7.61-7.66 (m, 2H), 7.76-7.82 (m, 4H). 13C-NMR (DMSO-d6), : 26.0, 40.0, 40.9, 52.4, 52.5, 54.8, 56.7, 126.4, 129.1, 129.2, 132.2, 140.4, 140.5. Anal. Calcd for 
C21H30N4O4S2: C, 54.05; H, 6.48; N, 12.01. Found: C, 53.82; H, 6.45; N, 12.13. MS [ESI, m/z]: 467.1 
[M+H]. 
 
4.1.8.16 4-tert-Butyl-N-(3-(4-(2-(4-tert-butylphenylsulfonamido)ethyl)-piperazin-1-yl)-propyl) benzene 
sulfonamide (36l) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 96:4 v/v. Obtained in 53% yield as a pale yellow solid. M.p. 86-88 °C. TLC (DCM-MeOH 9:1 
v/v, Rf: 0.55). 1H-NMR (DMSO-d6), : 1.30 (s, 9H), 1.31 (s, 9H), 1.41-1.49 (m, 2H), 2.05-2.21 (m, 12H), 
2.71-2.77 (m, 2H), 2.78-2.84 (m, 2H), 7.40 (bs, 1H), 7.49 (t, J= 5.2 Hz, 1H), 7.58-7.62 (m, 4H), 7.68-
7.73 (m, 4H). 13C-NMR (DMSO-d6), : 26.0, 30.7, 39.0, 40.0, 40.8, 52.4, 52.5, 54.8, 56.7, 125.8, 125.9, 
126.0, 126.3, 137.6, 137.7, 155.1. Anal. Calcd for C29H46N4O4S2: C, 60.17; H, 8.01; N, 9.68. Found: C, 
60.11; H, 8.22; N, 9.69. MS [ESI, m/z]: 579.2 [M+H]. 
 
4.1.9 General method for the preparation of amides 37 
The different 3-arylsulfonylamino propionic acid 10a-c, l, n (1.1 mmol) and TBTU (0.38 g, 1.2 mmol) 
were suspended in anhydrous THF (6 mL) at r.t. DiPEA (0.4 mL, 2.4 mmol) was then added to the 
reaction mixture, followed by the different N-(3-piperazin-1-yl-propyl)-arylsulfonamide 22a-c, l, n (1 
mmol). The reaction mixture was left stirring at r.t. for 4 h. The organic solvent was then removed at 
reduced pressure and the residue was diluted with EtOAc (30 mL). The organic layer was washed with 
saturated NaHCO3 solution (2 x 30 mL) and brine (30 mL). The organic solvent was removed under 
vacuum after drying over MgSO4. The crude residue was purified by flash column chromatography. 
 
4.1.9.1 4-Chloro-N-(3-(4-(3-(4-chlorophenylsulfonamido)propanoyl)piperazin-1-yl)-3-oxopropyl) 
benzenesulfonamide (37a) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 46% yield as a white solid. M.p. 72-74 °C. TLC (DCM-MeOH 9:1 v/v, Rf: 
0.48). 1H-NMR (CDCl3), : 1.64-1.70 (m, 2H), 2.37-2.34 (m, 6H), 2.54 (t, J= 5.2 Hz, 2H), 3.07 (t, J= 5.7 
Hz, 2H), 3.18-3.24 (m, 2H), 3.37-3.41 (m, 2H), 3.54-3.60 (m, 2H), 5.84 (bs, 1H), 6.63 (bs, 1H), 7.47-
7.51 (m, 4H), 7.78-7.82 (m, 4H). 13C-NMR (CDCl3), : 24.7, 32.8, 39.2, 41.5, 43.3, 45.0, 52.6, 52.7, 
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57.0, 128.4, 128.5, 129.3, 129.4, 138.7, 138.8, 138.9, 139.0, 169.41. Anal. Calcd for C22H28Cl2N4O5S2: 
C, 46.89; H, 5.01; N, 9.94. Found: C, 46.92; H, 4.76; N, 9.95. MS [ESI, m/z]: 563.1, 565.1 [M+H]. 
 
4.1.9.2 N-(3-(4-(3-(Phenylsulfonamido)propanoyl)piperazin-1-yl)-3-oxopropyl)benzene sulfonamide 
(37b) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 37% yield as a colourless waxy solid. M.p. 30-32 °C. TLC (DCM-MeOH 
9:1 v/v, Rf: 0.54).  1H-NMR (CDCl3), : 1.59-1.64 (m, 2H), 2.29 (t, J= 4.7 Hz, 2H), 2.32 (t, J= 4.7 Hz, 
2H), 2.37 (t, J= 6.0 Hz, 2H), 2.49 (t, J= 5.6 Hz, 2H), 3.04 (t, J= 6.0 Hz, 2H), 3.17-3.21 (m, 2H), 3.33 (t, 
J= 4.7 Hz, 2H), 3.50-3.54 (m, 2H), 5.80 (t, J= 6.2 Hz, 1H), 6.66 (bs, 1H), 7.48-7.52 (m, 4H), 7.54-7.58 
(m, 2H), 7.82-7.86 (m, 4H). 13C-NMR (CDCl3), : 24.8, 32.7, 39.2, 41.4, 43.1, 45.0, 52.5, 52.7, 56.8, 
126.8, 126.9, 129.11, 129.16, 132.55, 132.59 (CH, C-aromatic), 140.11, 140.21 (C, C-aromatic), 169.43 
(C, C-6’). Anal. Calcd for C22H30N4O5S2: C, 53.42; H, 6.11; N, 11.33. Found: C, 53.55; H, 5.89; N, 11.40. 
MS [ESI, m/z]: 495.1 [M+H]. 
 
4.1.9.3 4-Methyl-N-(3-(4-(3-(4-methylphenylsulfonamido)propanoyl)piperazin-1-yl)-3-oxopropyl) 
benzenesulfonamide (37c) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 34% yield as a white solid. M.p. 149-151 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.64). 1H-NMR (CDCl3), : 1.65-1.70 (m, 2H), 2.36-2.42 (m, 6H), 2.44 (s, 3H), 2.45 (s, 3H), 2.54 (t, 
J= 5.5 Hz, 2H), 3.10 (t, J= 5.8 Hz, 2H), 3.20-3.24 (m, 2H), 3.40 (t, J= 4.7 Hz, 2H), 3.59 (t, J= 4.7 Hz, 
2H), 5.52 (t, J= 6.7 Hz, 1H), 6.40 (bs, 1H), 7.31-7.35 (m, 4H), 7.75 (d, J= 8.3 Hz, 2H), 7.77 (d, J= 8.3 
Hz, 2H). 13C-NMR (CDCl3), : 21.2, 21.4, 24.6, 32.8, 39.1, 41.4, 43.5, 45.0, 52.7, 52.8, 57.4, 126.9, 
126.9, 129.6, 129.7, 137.1, 137.12, 143.2, 143.3, 169.4. Anal. Calcd for C24H34N4O5S2: C, 55.15; H, 
6.56; N, 10.72. Found: C, 54.96; H, 6.34; N, 10.56. MS [ESI, m/z]: 523.2 [M+H]. 
 
4.1.9.4 4-tert-Butyl-N-(3-(4-(3-(4-tert-butylphenylsulfonamido)propanoyl)piperazin-1-yl)-3-
oxopropyl)benzenesulfonamide (37l) 
Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 47% yield as a white solid. M.p. 189-191 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.61). 1H-NMR (CDCl3), : 1.36 (s, 9H), 1.37 (s, 9H), 1.66-1.71 (m, 2H), 2.37 (t, J= 5.0 Hz, 2H), 
2.42 (t, J= 5.0 Hz, 2H), 2.46 (t, J= 5.9 Hz, 2H), 2.57 (t, J= 5.6 Hz, 2H), 3.11 (t, J= 5.9 Hz, 2H), 3.21-
3.25 (m, 2H), 3.42 (t, J= 5.0 Hz, 2H), 3.60 (t, J= 5.0 Hz, 2H), 5.54 (t, J= 6.6 Hz, 1H), 6.28 (bs, 1H), 7.51-
7.55 (m, 4H), 7.78 (d, J= 8.5 Hz, 2H), 7.80 (d, J= 8.5 Hz, 2H). 13C-NMR (CDCl3), : 24.7, 31.1, 32.9, 
35.1, 39.1, 41.4, 43.4, 45.0, 52.7, 52.8, 57.2, 126.0, 126.1, 126.8, 137.0, 137.1, 156.2, 156.3, 169.4. Anal. 
Calcd for C30H46N4O5S2: C, 59.38; H, 7.64; N, 9.23. Found: C, 59.22; H, 8.01; N, 9.04. MS [ESI, m/z]: 
607.3 [M+H]. 
 
4.1.9.5 N-(3-(4-(3-(Biphenyl-4-ylsulfonamido)propanoyl)piperazin-1-yl)-3-oxopropyl) biphenyl-4-
sulfonamide (37n) 
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Purified by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-
MeOH 97:3 v/v. Obtained in 49% yield as a white solid. M.p. 176-178 °C. TLC (DCM-MeOH 9:1 v/v, 
Rf: 0.54). 1H-NMR (CDCl3), : 1.65-1.71 (m, 2H), 2.35-2.39 (m, 4H), 2.42 (t, J= 5.8 Hz, 2H), 2.56 (t, 
J= 5.5 Hz, 2H), 3.13 (t, J= 5.8 Hz, 2H), 3.25-3.29 (m, 2H), 3.40 (t, J= 4.6 Hz, 2H), 3.59-3.61 (m, 2H), 
5.75 (t, J= 6.3 Hz, 1H), 6.53 (bs, 1H), 7.40- 7.46 (m, 2H), 7.47-7.51 (m, 4H), 7.60-7.64 (m, 4H), 7.71-
7.75 (m, 4H), 7.91-7.96 (m, 4H). 13C-NMR (CDCl3), : 24.7, 32.8, 39.2, 41.5, 43.4, 45.1, 52.7, 52.8, 
57.1, 127.2, 127.3, 127.4, 127.5, 127.6, 128.0, 128.4, 128.5, 129.0, 129.1, 138.7, 138.8, 139.2, 139.3, 
145.4, 145.5, 169.4. Anal. Calcd for C34H38N4O5S2: C, 63.13; H, 5.92; N, 8.66. Found: C, 63.18; H, 5.87; 
N, 8.79. MS [ESI, m/z]: 647.2 [M+H]. 
 
4.1.10 Synthesis of 4-chloro-N-(3-(piperidin-1-yl)propyl)benzenesulfonamide (39) 
Piperidine 38 (0.1 mL, 1.2 mmol) and NaHCO3 (0.11 g, 1.3 mmol) were suspended in 9 mL of absolute 
EtOH. N-(3-Bromopropyl)-4-chlorobenzenesulfonamide 6a was then added portionwise to the 
suspension and the mixture was stirred under reflux for 24 h. The reaction mixture was then concentrated 
under reduced pressure. The residue was diluted with EtOAc (30 mL), washed with water (3 x 30 mL) 
and the organic phase was concentrated under vacuum after drying over MgSO4. The residue was purified 
by flash column chromatography eluting with DCM-MeOH 100:0 v/v increasing to DCM-MeOH 93:7 
v/v to give the title compound as a pale yellow oil in 85% yield. TLC (DCM-MeOH 95:5 v/v, Rf: 0.30). 
1H-NMR (CDCl3), : 1.50 (m, 2H), 1.67 (m, 6H), 2.43 (m, 6H), 3.09 (t, J= 5.3 Hz, 2H), 7.50 (d, J= 8.5 
Hz, 2H), 7.82 (d, J= 8.5 Hz, 2H). 13C-NMR (CDCl3), : 23.60, 24.00, 25.70, 44.32, 54.39, 58.71, 128.42, 
129.21, 138.61, 138.98. Anal. Calcd for C14H21ClN2O2S: C, 53.07; H, 6.68; N, 8.84. Found: C, 53.05; H, 
6.64; N, 8.87. MS [ESI, m/z]: 317.1, 319.1 [M+H]. 
 
4.2 Molecular Modelling 
Molecular modelling simulations were performed on a MAC pro 2.66 GHz Quad-Core Intel Xeon, 
running Ubuntu. Molecular Operating Environment (MOE) 2014.10 [29] and Maestro (Schrodinger 
version 9.0) [30] were used as molecular modelling softwares. All minimisations were performed with 
MOE 2014.10 until RMSD gradient of 0.001 Kcal mol-1 Å-1 with the AMBER99 force field. Partial 
charges were automatically calculated. Conformational analyses were performed with MOE 2010.10; 
conformers with a strain energy >4 kcal/mol were discarded, and the maximum number of conformations 
per ligand was set to 500. In every step MOE default settings were applied. Pharmacophoric filters were 
created within MOE 2010.10 choosing the PCH (polar-charged-hydrophobic) scheme. Docking 
experiments were carried out using GlideSP module in Maestro [30] with the default options. A 12 Å 
docking grid was generated using as centroid defined by Asp296, Arg393 and Trp501 in the 3KQN and 
3KQH crystal structures. Docking results were rescored using FlexX [32], Plants ChemPLP [33] and 
Glide XP [30] scoring functions. 
 
4.3 HCV replicon assay 
The compounds were dissolved in dimethyl sulfoxide, stored at -20 °C protected from light and further 
diluted in culture medium prior to use. The Huh 5-2 HCV subgenomic replicon-containing cells were 
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provided by Prof. R. Bartenschlager (University of Heidelberg, Heidelberg, Germany). Huh 5.2 cells, 
containing the hepatitis C virus genotype 1b I389luc-ubi-neo/NS3-3’/5.1 replicon were sub-cultured in 
DMEM supplemented with 10% FCS, 1% non-essential amino acids, 1% penicillin/streptomycin and 
2% Geneticin at a ratio of 1:3 to 1:4, and grown for 3-4 days in 75 cm2 tissue culture flasks. One day 
before addition of the compound, cells were harvested and seeded in assay medium (DMEM, 10% FCS, 
1% non-essential amino acids, 1% penicillin/streptomycin) at a density of 6 500 cells/well (100 μL/well) 
in 96-well tissue culture microtiter plates for evaluation of anti-metabolic effect and CulturPlate (Perkin 
Elmer) for evaluation of the antiviral effect. The microtiter plates were incubated overnight (37 °C, 5% 
CO2, 95-99% relative humidity), yielding a nonconfluent cell monolayer. The evaluation of the anti-
metabolic as well as antiviral effect of each compound was performed in parallel. 
Four-step, 1-to-5 compound dilution series were prepared for the first screen, to collect data for a more 
detailed dose-response curve, an eight-step, 1-to-2 dilution series was used. Following assay setup, the 
microtiter plates were incubated for 72 hours (37 °C, 5% CO2, 95-99% relative humidity). For the 
evaluation of anti-metabolic effects, the assay medium was aspirated, replaced with 75 μL of a 5% MTS 
solution in phenol red-free medium and incubated for 1.5 hours (37 °C, 5% CO2, 95-99% relative 
humidity). Absorbance was measured at a wavelength of 498 nm (Safire2, Tecan), and optical densities 
(OD values) were converted to percentage of untreated controls. For the evaluation of antiviral effects, 
assay medium was aspirated and the cell monolayers were washed with PBS. The wash buffer was 
aspirated, and 25 μL of Glo Lysis Buffer (Promega) was added allowing for cell lysis to proceed for 5 
min at room temperature. Subsequently, 50 μL of Luciferase Assay System (Promega) was added, and 
the luciferase luminescence signal was quantified immediately (1000 ms integration time/well, Safire, 
Tecan). Relative luminescence units were converted into percentage of untreated controls. 
The EC50 and EC90 (values calculated from the dose-response curve) represent the concentrations at 
which 50% and 90% inhibition, respectively, of viral replication is achieved. The CC50 (value calculated 
from the dose-response curve) represents the concentration at which the metabolic activity of the cells is 
reduced by 50% as compared to untreated cells. 
 
4.4 HCV NS3 helicase enzymatic assays 
The ability of compounds to inhibit HCV helicase-catalysed nucleic acid unwinding was determined 
using molecular beacon-based NS3 helicase assays as described by Hanson et al. [39] Reactions 
contained 25 mM MOPS pH 6.5, 1.25 mM MgCl2, 5% DMSO, 5 µg/ml BSA, 0.01% (v/v) Tween20, 
0.05 mM DTT, 5 nM florescent DNA substrate, 12.5 nM NS3h, and 1 mM ATP. 
The ability of compounds to displace NS3 from a DNA oligonucleotide was monitored as described by 
Mukherjee et al. [40].  Each assay contained 15 nM NS3h, 25 mM MOPS, pH 7.5, 1.25 mM MgCl2, 
0.0025 mg/ml BSA, 0.005% (v/v) Tween20, 0.025 mM DTT and 12.5 nM NS3h. 
The ability of NS3 to hydrolyse ATP was monitored as described by Sweeney et al. [41].  Reactions 
performed in the presence of RNA contained 25 mM MOPS pH 6.5, 1.25 mM MgCl2, 15 µM poly(U) 
RNA (Sigma), 6 nM NS3h in 5 μg/mL BSA, 0.001% Tween 20. 
To determine the compound concentration needed to reduce  activity by 50 % (IC50) in each of the above 
assays, reactions were performed in duplicate two-fold dilution series such that final compound 
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concentrations ranged from 1 mM to 0.78 µM. Data obtained from all reactions within the linear range 
of the assays were normalized to controls lacking inhibitor (100%) and controls lacking enzyme (0%), 
and fit to a normalized dose response equation with a variable Hill slope using GraphPad Prism (v. 6). 
Average IC50 values ± standard deviations are reported. 
To determine the amount of RNA needed for half maximal stimulation of ATP hydrolysis (KRNA), steady 
state rates were fit to Eq. 1: 
V=(Vmax*R/KRNA+R)+ Vb      (Eq. 1) 
In equation 1, Vmax is maximum ATP hydrolysis rate, R is the concentration of poly(U) RNA, and Vb is 
the basal rate of ATP hydrolysis in the absence of RNA.  
Direct binding assays using intrinsic protein fluorescence were performed as described by Ndjomou 
(2012) [42] using truncated NS3 lacking the protease domain (NS3h) isolated from the JFH1 strain of 
HCV genotype 2a.  After correcting for dilution and inner filter effects, fluorescence intensities 
(excitation: 280 nm, emission: 340 nm) were fit to Eq. 2. 
F=Fe*(E-EL) + Fs*(L- EL) + Fc*(EL)        (Eq. 2) 
where EL=((Kd + L+ E)-sqrt((Kd + L+ E)2-4*(L* E)))/2 
In eq. 1, L is the total concentration of compound 13, E is the concentration of NS3h, Kd is the 
dissociation constant describing complex formation, Fe is coefficient describing free protein 
fluorescence, Fs is a coefficient describing free compound 13 fluorescence, and Fc is a coefficient 
describing the fluorescence of the protein-ligand complex.   
 
List of abbreviations 
pegIFN= pegylated-Interferon 
DAAs= Direct-Acting-Antivirals 
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